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ABSTRACT

Angelman Syndrome (AS) is a severe neurodevelopmental disorder that affects
1:12000 newborns. It is characterized by mental retardation, delayed major motor and
cognitive milestones, seizures, absence of speech and excessive laughter. The majority
of AS cases arise from deletions or mutations of UBE3A gene located on the
chromosome 15q11-13. UBE3A codes for E3-ubiquitin ligase that target specific proteins
for degradation. To date, a wide variety of Ube3a substrates has been identified. The
accumulation of Ube3a-dependent proteins and their effect on the multitude of signal
transduction pathways are` considered the main cause of the AS pathology. While the
majority of research has been directed towards target identifications, the overall role of
Ube3a in activity-dependent synaptic plasticity has been greatly overlooked.

The

present work is designed to fill some of these knowledge gaps.
Chapter 2 is focused on the activity-dependent aspect of Ube3a expression
following neuronal stimulation in vivo and in vitro. We examined total Ube3a expression
followed by KCl depolarization in neuronal primary culture. By utilizing a subcellular
fractionation technique, we were able to determine which cellular pools are responsive to
the depolarization. Next, a fear conditioning paradigm (FC) was used to activate neurons
in the paternal Ube3a-YFP reporter mouse brain. This mouse model allowed us to
resolve spatial and temporal alterations of the maternal and the paternal Ube3a in
hippocampus and cortex followed by FC. In accordance to KCl depolarization results,
we observed alterations in Ube3a protein but at later time points. Furthermore, we
investigated if the absence of activity-dependent Ube3a changes has any effect on
ix

learning and memory kinase activation. We utilized KCl and FC to determine synaptic
activity-induced ERK 1/2 phosphorylation in acute hippocampal slices and in CA1 area
of hippocampus of wild type (Ube3a m+/p+) and Ube3a deficient mice (Ube3a m-/p+).
We demonstrated that Ube3a loss leads to impaired activity-dependent ERK 1/2
phosphorylation.
It has been established that Ube3a m-/p+ mice have a profound deficit in LTP,
implying the importance of this ligase in excitatory synaptic transmission. The abnormal
LTP could be partially explained by an aberrant CaMKII function, decreased activitydependent ERK 1/2 phosphorylation and reduced phosphatase activity. These proteins
have also been implicated in another form of synaptic plasticity such as long-term
depression (LTD). Chapter 3, we investigated the contribution of Ube3a to NMDAR –
dependent and – independent LTD. Our data showed that Ube3a m-/p+ P21-30 animals
exhibit the impairments in both forms of LTD. Next, we focused on elucidating molecular
mechanism underlying the reduced mGluR1/5–LTD. We discovered that mGluR1/5
kinase activation such as ERK, mTOR and p38 is not affected by Ube3a loss. In
concordance with previous work, we detected increased Arc expression together with
abnormal AMPAR distribution in the Ube3a m-/p+ hippocampus. Surprisingly, the
mGluR1/5 induced GluR2 trafficking was normal. Our findings infer that elevated Arc
levels together with the increased internalization of AMPAR may result in compromised
basal state of the synapses leading to a more depression-like state in Ube3a m-/p+
mice.
Evidence points that loss of Ube3a produces alterations in a variety of activity–
dependent signal transduction cascades that may ultimately result in impaired synaptic
plasticity and cognition. Similar to AS, abnormal molecular and behavioral phenotypes
have already been observed in other mouse models of human mental retardation such
as Fragile X Mental Retardation Syndrome (FXS). Chapter 4 is set to explore if any
x

correlation can be found in between these neurodevelopmental disorders. Analysis of
crude synaptoneurosomes of adult Fmr1 KO mice revealed a significant reduction in
Ube3a protein. Additionally, a blunted translation of Ube3a in response to mGluR1/5
stimulation was observed. However, we didn‘t find any evidence of direct interaction
between Ube3a mRNA and Fragile X Mental Retardation Protein (FMRP). To examine if
some of the pathology seen in Fmr1 KO mice is due to Ube3a downregulation, we
performed a rescue experiment by increasing overall levels of Ube3a in hippocampus of
FRMP deficient mice. An exhaustive battery of behavioral testing indicated that
alterations of Ube3a expression impacted only associative fear conditioning.
In summary, the present work has attempted to answer some of the fundamental
questions about Ube3a and its role in synaptic plasticity. We have demonstrated that
Ube3a expression is modulated by synaptic activation and its activity-dependent
alterations are essential for normal brain functioning. Additionally, our data suggest that
Ube3a is not only significant for the synaptic excitation but also crucial for the synaptic
depression. Finally, our findings indicate that the alteration of Ube3a expression may
contribute to the cognitive phenotypes in other neurodevelopmental disorders such as
FXS suggesting an advantage of exploring Ube3a function outside the AS research.

xi

CHAPTER 1: INTRODUCTION

1.1 Preamble
A picture of a red-haired boy holding a drawing by Geovanni Francesco Caroto
has been a highlight of the art exhibitions throughout Europe (Figure 1 A). Scholars have
debated the meaning of the child‘s drawing: whether the artist was imitating the
primitivism of a childhood art or wanted to highlight the gap between our own perception
and the others‘ is unclear. Unexpectedly, apart from the artistic value, this portrait gained
significance in natural science where it became a ―ground zero‖ for Angelman Syndrome
(AS) research. This piece of art once inspired Dr. Harry Angelman to publish the first
case study of 3 unrelated young children that he observed during his medical practice in
England (Figure 1 B). In his article ―Happy Puppet Syndrome‖ Dr. Angelman first
described the unique characteristics of the disorder: severe developmental delay, ataxia,
seizures and happy demeanor (Angelman 1965). His description of 6 distinctive features
related to the impairment of the CNS (protruding tongue, seizures, etc.) and one
behavioral trait - outbursts of laughter - is still valid for most individuals affected by this
rare disorder. Unfortunately, Happy Puppet Syndrome, later renamed to Angelman
Syndrome, was almost forgotten until 1980s when Dr. Magenis linked AS to defects in
the maternal chromosome 15 (Magenis et al. 1987). Ever since, the number of scientific
publications has been increased annually reflecting a growing interest in the scientific
community.

1

A.

B.

Figure 1. A. ―Portrait of a Young Boy holding a Child's Drawing‖ (1515) by Geovanni
Francesco Caroto (Italian, ca.1480-1555) first inspired Dr. Harry Anglelman to publish
―Puppet‖ children‖, a case study report of three children affected by Angleman
syndrome (B.).

2

1.2 Clinical and neurological features of Angelman Syndrome
Currently, most AS researchers agree on the common neurological features that
present in almost 100% of the AS patients: severe mental retardation, seizure, abnormal
movement and absence of speech (Williams et al. 2006; Dagli et al. 2011). From a very
early age, AS children fail to reach most developmental milestones: they sit unsupported
at 12 months and walk at mean age of 4 years old. Many of them develop tremors in the
fingers and jerky movements in addition to a slow ataxic gait and sometimes muscle
hypotonia (Clayton-Smith and Laan 2003). All of the neurological symptoms other than
the behavioral phenotype are non-specific and may be present in a wide variety of
syndromes ranging from autism spectrum disorder (ASD) to fragile X mental retardation
(FXS). Therefore, only behavioral traits including but not limited to excessive laughter,
fascination with water and hyperactivity serve as a hallmark for AS and are employed to
distinguish it from other disorders of central nervous system (CNS). Evidence suggests
that the first and foremost noticeable symptoms of an AS child is an early onset of social
smiling that could be seen even in 1-3 months old infants. Later, subsequent giggling is
replaced by contagious ―bursts of laughter‖, happy disposition and happy grimacing
observed in 77% of infants (Buntinx et al. 1995). Interestingly, paroxysms of laughter
are still present in adulthood, but less frequently than in early age (Laan et al. 1996). It is
worth noting that the persistent smiling doesn‘t indicate that individuals with AS are not
capable of experiencing negative emotions such as anger, frustration and sadness.
Furthermore, sleep problems such as difficulties maintaining sleep, irregular
sleep-wake cycles, inappropriate nocturnal behaviors and sleep movement disorders are
repeatedly reported by the parents of AS individuals (Clayton‐Smith 1993; Didden et al.
2004; Pelc et al. 2008). The abnormal sleeping patterns suggest that the development
and/or function of thalamocortical network may be perturbed; however, more research is
needed to make any reliable conclusions. Interestingly, sleep disturbances and shorter
3

than normal sleep duration doesn‘t affect children‘s daytime routine suggesting the
―diminished need for sleep‖ (Clayton‐Smith 1993). Some investigators attribute

the

abnormal sleep patterns to increased anxiety that manifests itself not only through
frequent night wakening and sleep walking but also hyperactive and excitable behavior
during daytime (William, 2004). Currently, behavioral modifications as well as melatonin
treatment are prescribed to alleviate the symptoms (Zhdanova et al. 1999).
Seizures are present in 85% of patients and often observed within the first 36
months of life (Clayton‐Smith 1993). The most frequent seizure types are atypical
absences, generalized tonic-clonic, atonic or myoclonic seizers (Laan and Vein 2005).
Three common EEG patterns are usually observed: 1) persistent generalized rhythmic 46 Hz activity not influenced by eye closure; 2) rhythm delta activity of 2-3 Hz more
evident in the anterior regions; 3) spikes and sharp waves mixed with 3-4 Hz
components of amplitude higher than 200 μM mainly from the posterior area and
triggered by eye closure (Viani et al. 1995). The described EEG abnormalities are
routinely used to diagnose AS before any cytogenetic analysis is conducted (Buoni et al.
1999).
Despite the great expansion and availably of modern imaging technology, there
are not many conclusive neuroimaging results that could explain some of the
neuropathology of AS. Early studies via computed tomography (CT) scan revealed an
abnormal scull with diffuse cortical – subcortical brain atrophy and irregular distribution
of neurons was observed in layer III with variation in their density (Dörries et al. 1988;
Jay et al. 1991; Kyriakides et al. 1992; Clayton-Smith and Laan 2003). Moreover, MRI
studies indicate that an AS brain may lack a typical organization. For example,
examination of the banks and branches of the Sylvian fissure of 7 AS patients reveals
an abnormal organization of the supramarginal gyrus on the left manifested in increased
convolutions and often split between the motor and somatosensory strips (Leonard et al.
4

1993). Additionally, AS individuals display decreased/delayed myelination, decreased
axonal density or diameter, and aberrant axonal organization (Peters et al. 2011). It
could be concluded that despite a relatively normal appearance, AS brain may have
small anatomical alterations. Nevertheless, more research is needed to pinpoint specific
brain area deviations that are responsible for the overt symptomology.
Regardless of the severity of neurological symptoms present in AS, the affected
individuals have a relatively normal life span and some of them successfully reach
adolescence and even old age (53-75 years old). Unfortunately, the symptomology
doesn‘t improve with age and contrarily the physical conditions are exacerbated. For
instance, many of the individuals develop thoracic scoliosis ,truncal hypotonia (71%) and
finally become wheelchair-bound (39%). The majority of the adult AS population still
exhibits an ataxic puppet-like gait, seizures and distinctive facial features that become
more pronounced than in childhood. Even if 86% can non-verbally communicate with the
caregivers and 85% are able to perform simple task, AS children and adults still require
constant medical attention and homecare due to the severe mental retardation that
doesn‘t improve with maturation (Laan et al. 1996).
Despite precise diagnostic tests, there are no options available for managing the
symptoms, other than seizure control. Several experimental treatments such as
levodopa, prednisolone, folic acid and minocycline are currently being investigated as a
potential therapeutics, but whether these treatments whether show effectiveness or not
remains to be seen since the data are still being collected (Hulten et al. 1991; Harbord
2001; Forrest et al. 2009).

1.3 Genetic causes of Angelman Syndrome
AS is usually diagnosed within the first few years when a child starts exhibiting
true delays in motor and cognitive development. However, there are a few syndromes
5

such as Rett, Christenson, Mowat-Wilson and FXS that can somewhat mimic the AS
phenotype. As a result, the diagnosis can only be determined by cytogenetic analysis of
chromosome 15 q11-13. Currently, there are 4 genetic causes of AS which are
associated with chromosome 15 q11-13: various de novo microdeletions (5-7Mb) (70%),
uniparental paternal disomy (2%), defects in the imprinting center (5%) and mutations in
UBE3A gene (5-10%) (Lossie et al. 2001; Clayton-Smith and Laan 2003; Dagli et al.
2011). The 5th class, a fairly large subset of the population (12-15%) with clinical AS
characteristics, has no identifiable genetic deficits related to the AS chromosomal region.
Recently, mutations in SLC9A6 and HERC2 have been reported in latter group (Gilfillan
et al. 2008). This discovery raised an important possibility that many genes might be
involved in the etiology of AS. Nevertheless, until a thorough genomic analysis of the 5 th
class of patients is conducted, AS is considered a monogenetic disorder involving
disrupted maternal Ube3a gene expression.

1.4 Ube3a is a genetic locus for Angelman Syndrome
Ube3a is one of 100-200 imprinted genes identified in humans and mice.
Imprinting refers to an epigenetic mechanism that leads to differential gene expression
depending on the parent-of-origin inheritance. In most cases, imprinted genes exist in
clusters called microdomains. One such microdomain is present on the human
chromosome 15 q11-13, homologous to the mouse chromosome 7, and is implicated in
several neurodevelopmental disorders such as AS, Prader-Willi Syndrome and ASD. A
high proportion of imprinted genes found in both the placenta and CNS follow a general
rule that if a gene is imprinted in the brain, it is also silenced in other tissue. On the
contrary, Ube3a together with NNAt and Muurl shows mainly brain-specific imprinting
and biallelic expression in somatic cells. Specifically, in situ hybridization reveals the
presence of monoallelic maternal Ube3a mRNA in hippocampus and Purkinje cells,
6

while biallelic Ube3a transcripts are seen in the prefrontal cortex, cortex and the
cerebellum (Jiang et al. 1998) . Biochemical studies of Ube3a protein in the AS mouse
model show a complete absence of maternal Ube3a protein in CNS and reduced total
expression in other tissue (Gustin et al. 2010). Similar observations were made in
human brain samples (Daily et al. 2012). The discrepancies between Ube3a mRNA and
protein expressions could be explained by a brain region-specific differential regulation
of Ube3a; however, more experimentation is needed to determine the mechanism.
Epigenetic silencing is usually accomplished through DNA methylation, histone
modification and long non-coding RNA. Genetic mechanisms that govern paternal
Ube3a imprinting belong to the latter category; however, the complete process is still
poorly understood (Lalande and Calciano 2007). The paternal gene is thought to
express large (<600 bp) non-coding antisense RNA (Ube3a-ATS) that is initiated in the
Prader-Willi syndrome–imprinting center (PWS-IC). Once transcribed, Ube3a-ATS
undergoes alternative splicing and inactivates paternal Ube3a expression. There are
several mechanisms proposed by which processed Ube3a-ATS could mediate
epigenetic silencing: (i) transcriptional interference resulting from the simultaneous
occupancy of RNA polymerase complexes; (ii) RNA interference induced by doublestranded RNA formed between sense and antisense RNAs or (iii) conformational
chromatin change that results in transcription repression (Lalande and Calciano 2007;
Mabb et al. 2011).
In AS, the maternal Ube3a gene is absent or non-functioning while the paternal
gene is intact, but dormant, making it an appealing therapeutic target. It has already
been demonstrated that the paternal Ube3a imprinting can be reversed genetically by
disrupting the Ube3a-ATS or pharmacologically by the administration of topoisomerase
inhibitors (Huang et al. 2011; Meng et al. 2012). Unfortunately, both approaches cannot
be applied to human patients due to the methodological limitation or drug toxicity.
7

Nevertheless, these studies lay a foundation for future research by providing evidence of
reversible epigenetic repression.
A preponderance of work suggests that the expression of Ube3a is critical for
normal CNS functioning. In humans, the absence of the maternal Ube3a leads to AS
while the duplication of Ube3a results in the symptoms similar to ASD (Samaco et al.
2005; Schanen 2006). Analogously, in mice loss of maternal Ube3a expression results in
cognitive and motor defects (Jiang et al. 1998; Miura et al. 2002). In contrast, increased
levels of Ube3a culminate in poor social interaction, behavioral inflexibility, and anxiety
(Nakatani et al. 2009; Smith et al. 2011). Intriguingly, Ube3a expression in the nonmammalian systems appears to be important as well. The loss of dUbe3a protein in
Drosophila causes abnormal locomotive behavior and circadian rhythm, and defects in
long-term memory. Conversely, flies that overexpress dUbe3a also display locomotion
defect in addition to decreased dendritic branching in sensory neurons in the peripheral
nervous system (Wu et al. 2008).

1.5 Ube3a codes for E3 ubiquitin ligase
The Ube3a gene, or E6-AP, was mapped as the genetic locus for AS in 1997
(Kishino et al. 1997; Matsuura et al. 1997). However, it was first described in the
relationship to cervical cancer. E6-AP was discovered to be associated with E6
oncoprotein of the human papiloma virus, resulting in increased cell proliferation and
tumor growth through the degradation of tumor suppressor p53 (Scheffner et al. 1993).
Ube3a encodes a 100 kDa homologous to E6-AP carboxyl terminus (HECT) E3 ligase
that is involved in protein degradation via the ubiquitin–associated proteosome-mediated
pathway (UPS). E3 ligases are a very diverse group of proteins that are important for the
recognition of specific substrates and their subsequent ubiquitination within proteolytic
system. HECT E3 ligases are characterized by a highly conserved catalytic C-terminus
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domain that harbors an active cysteine (Cys) residue. This Cys forms a strong thioester
bond with an ubiquitin carried by E2 ligase and transfers it to a target protein. Similarly,
Ube3a recognizes its substrates via its N-terminal domain and tags them with Lys48linked ubiquitin chain that is ultimately identified by 26S proteasomes and degraded. A
variety of Ube3a targets have been identified including but not limited to p53, Rad23,
MMP7, E6-AP, sacsin, RhoGEF ephexin5, Arc and Rpn10 (Huibregtse et al. 1991;
Kühne and Banks 1998; Nuber et al. 1998; Kumar et al. 1999; Greer et al. 2010;
Margolis et al. 2010; Lee et al. 2013). Table 1 summarizes all the major Ube3adependent proteins and their functions.
The Ube3a protein is highly expressed in somatic cells as well as in neurons and
glia (Dindot et al. 2008). It is produced in high levels in the soma and to a lesser degree
in dendrites in both excitatory and inhibitory neurons (Wallace et al. 2012). It primarily
resides in cytoplasmic and nuclear cellular compartments. Ube3a is subjected to the
alternative splicing generating 3 isoforms (Iso) (Yamamoto et al. 1997). Iso2
corresponds to the full length protein while Iso1 and Iso3 both lack 21 amino acids from
N-terminus. Iso1 is considered to be E3-ligase deficient since it is additionally missing 87
amino acids from the C-terminal HECT domain. Interestingly, while Iso1 and Iso2 are
ubiquitously found throughout a cell, Iso3 is confined to the nucleus where it seems to
have an important place for the embryonic development (Miao et al. 2013). Total levels
of Ube3a protein fluctuate with age. All the isoforms, especially Iso3, are highly enriched
in the embryonic brain (E15 cortex); however, the expression gradually declines when
the brain matures. Subcellular Ube3a localization also appears to be developmentally
determined. Immunohistological data suggests an active Ube3a trafficking from
cytoplasm to the nucleus occurring postnatally. Specifically, Ube3a staining shows
almost exclusive cytoplasmic localization at P0 mouse brain; however, it is mainly found
in the nucleus by P28. Close examination of maternal and paternal Ube3a demonstrates
9

that paternal Ube3a imprinting is more relaxed in neonates. Paternal Ube3a is abundant
in cytoplasm until P7 when its production rapidly decreased to about 5% and remains
the same throughout the adulthood. Conversely, hippocampal stem cells and
oligodendrocytes exhibit billelic expression in young and aged animals (Judson et al.
2013).

1.6 Murine models for Angelman Syndrome
Several mouse models have been created to study the role of Ube3a in CNS. A
murine Ube3a located on chromosome 7 shows similar to humans imprinting patterns;
therefore, in vivo modeling of AS follows maternal inheritance and involves a disruption
of maternal Ube3a gene. Paternal Ube3a deletion is often used as a study control.
The first mouse model was generated in 1997 by knocking out 3 kb of exon 2 of
human UBE3A (Jiang et al. 1998). The mutation resulted in a frame shift causing null
Ube3a expression in all brain regions (Gustin et al. 2010). This transgenic mouse model
quickly gained favor as it nicely recapitulated hallmark clinical AS phenotypes. The
Ube3a deficient animals (Ube3a m-/p+) displayed abnormalities in gait (increased both
hind stride length and hind base width), motor learning and coordination (rotarod, wire
hang and beam crossing tests) (Jiang et al. 1998; van Woerden et al. 2007; Heck et al.
2008). These deficits are often explained by the lack of Ube3a in Purkinje cells of
cerebellum together with increased body weight and decreased muscle tone (grip
strength). Interestingly, a recent study reported deficits in dopamine-dependent tasks
including but not limited to foot clasping behavior and pole and adhesive tape removal
tests suggesting that motor deficits can also be attributed to a reduction in the number of
dopaminergic neurons observed in the AS substantial nigra (Mulherkar and Jana 2010).
In addition to impaired motor coordination, Ube3a deficient mice show cognitive
dysfunction that manifests in poor performance in the hippocampal-dependent tasks
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such as contextual fear conditioning and hidden platform water maze (Jiang et al. 1998;
van Woerden et al. 2007). Consistent with AS patients, epilepsy in the forms of
spontaneous and audiogenic seizures and abnormal EEG patterns are present in Ube3a
m-/p+ animals, especially in the 129 Sv strain.
Furthermore, this transgenic mutant exhibits several behaviors that reflect some
of nuanced symptoms seen in the AS population. For example, it has been reported that
Ube3a m-/p+ mice show an abnormal licking rhythms during water consumption. This
deficit

implies the weakened cerebellar coordination between licking, breathing and

swallowing and closely resembles difficulties in swallowing observed in 77% of AS
individuals (Williams et al. 2006; Heck et al. 2008). However, despite the many
similarities, the Ube3a m-/p+ mice don‘t mimic hyperactivity and increased sociability of
AS individuals. In contrast, AS mouse show increased body weight, reduction in motor
activity and normal social behavior (Allensworth et al. 2011).
A second AS mouse model was engineered by replacing parts of exon 15 and
full exon 16 of human UBE3A gene with a β-galactosidase (LacZ) transcriptional reporter
to inactivate the maternal Ube3a (Miura et al. 2002). In accordance with the first
mutation model, these animals are characterized by deficits in motor and hippocampaldependent learning. Additional phenotypes such as sleep disturbances, elevated
Purkinje cell firing and rhythmicity have also been detected (Chéron et al. 2005; Colas et
al. 2005).
While Ube3a knockouts are sufficient to study Ube3a contribution to AS, the
mutations in Ube3a are found only approximately 15% of all AS cases. The majority of
affected individuals carry a large ~6Mb deletion in 15 q11-13 region. Therefore, to better
represent the diseased state, a new transgenic mouse was made by a ~1.6 Mb maternal
deletion that disrupted not only Ube3a but also Atp10a and Gabrb3 genes (Jiang et al.
2010). Similarly to the deletion mutants, this mouse has abnormal EEG patterns and
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seizure phenotype. Motor and cognitive dysfunctions are also present. Increase in
ultrasonic vocalization was found in young pups suggesting abnormal signaling or
communication between the mother and Ube3a m-/p+ offsprings. This discovery may
signify a similar behavior that is often seen in AS children: a compensatory increase in
laughter and smiling during communication with adults. Unfortunately, it is not clear what
specific genes are involved in the abnormal ultrasonic vocalization since this paradigm
has never been tested in the Ube3a knockout mice.
The contribution of the paternal Ube3a to the mouse behavior has been
extensively studied as well. It has been established that the animals carrying either null
mutations or large deletion on the paternal chromosome show no differences in EEG,
seizures or general behavior compared to the wild type littermates (Jiang et al. 1998;
Jiang et al. 2010). A single study points to a significant difference between complete
knockout mice (Ube3a m-/p-) and maternal Ube3a m-/p+ in licking behavior and beam
test alluding that paternal Ube3a may play some role in cerebellum-dependent behavior
(Heck et al. 2008).
Finally, a Ube3a-Yellow Fluorescent Protein (YFP) reporter mouse was created
in the laboratory of Dr. Beaudet by fusing YFP to the C-terminus of Ube3a (Dindot et al.
2008). This Ube3a-YFP mutant is particularly useful for visualization of the cellular
Ube3a localization and for separate examination of maternal and paternal Ube3a
expression in primary neurons and in the intact mouse brain. Most importantly, it
provides a valuable tool in a pharmacological quest to ―unsilence‖ paternal Ube3a.
Primary cultures obtained from the paternal Ube3a-YFP mouse have already been
utilized in drug discovery experiments leading to identification of topoisomerase
inhibitors as the first molecule cable to overcome epigenetic down-regulation of a
paternal gene (Huang et al. 2011).
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1.7 Alteration in synaptic plasticity in Angelman Syndrome mouse model
The ubiquitin proteolytic system (UPS) is an important component of normal
neuronal function. Pioneer studies of long-term facilitation in Aplysia first linked UPS to
synaptic plasticity by demonstrating that protein kinase A (PKA) is regulated by a deubiquitylating enzyme (Hegde et al. 1997; Hegde and DiAntonio 2002). Significantly,
Ube3a became the first UPS enzyme associated with normal cognitive processes in
humans and mice.
The observations that disruption in maternal Ube3a leads to impaired cognition
raised an important question about Ube3a contribution to synaptic plasticity. First
electrophysiological study of CA3-CA1 pathway in hippocampus of Ube3a deficient mice
revealed a profound decrease in long-term potentiation (LTP) induction and
maintenance (Jiang et al. 1998). A detailed investigation of hippocampal plasticity
demonstrated that lack of maternal Ube3a results in both N-Methyl-D-aspartic acid
receptor (NMDAR) - dependent and –independent LTP deficits. Interestingly the inability
of the pyramidal neurons to maintain normal LTP expression was overcome by
increasing slice temperature and stimulation intensity implying an abnormal increase in
LTP induction threshold in CA1 area of AS mice. Further biochemical analysis
uncovered that Ube3a m-/p+ have

increased Ca2+ /Calmodulin-Dependent Protein

Kinase II (CaMKII) phosphorylation at autophosphorylated autonomously active Thr286
and inhibitory Thr305/306 sites together with decreased protein phosphatase 1 (PP1)/
protein phosphatase 2 (PP2a) phosphatase activity (Weeber et al. 2003). Later, a double
mouse mutant was created by crossing the AS mouse with a heterozygous mouse that
carried a CaMKII Thr305 mutated site. The mutation to CaMKII prevented the inhibitory
Thr305 phosphorylation and restored normal CaMKII activity. The Ube3a m-/p+/CamKII
Thr305 double mutant mouse showed no motor or cognitive deficits when compared to
Ube3a m-/p+ littermate controls (van Woerden et al. 2007). This finding suggests that
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defective CaMKII phosphorylation and activity is important in AS etiology; however, the
mechanism by which Ube3a modulates the kinase remains unknown.
Conceivably, deficits in synaptic plasticity are not only confined to hippocampal
formation; thus, similar observations have already been reported in other brain regions.
Several publications have documented abnormal neocortical synaptic development and
plasticity in visual cortex (layer II-IV) in young and adult Ube3a m-/p+ mice. Specifically,
the normal developmental increase in the frequency of mature excitatory post-synaptic
potentials (mEPSP) was not detected in the Ube3a m-/p+ P11-12 animals. Moreover, a
bidirectional impairment of NMDA-dependent LTP and LTD was also observed.
Interestingly, similarly to hippocampus, neocortical LTP was rescued by stronger LTP
stimulation protocol implying analogous biochemical mechanisms that underlie the
defective excitatory transmission in both brain regions. Surprisingly, no CaMKII changes
were identified in juvenile cortex (Yashiro et al. 2009). In depth investigation of inhibitory
interneurons and excitatory pyramidal cells in layers II-III of visual cortex revealed an
excitatory/inhibitory imbalance. It appears that reduction in maternal Ube3a affects both
inhibitory and excitatory cell firing since the diminished mEPSP and mIPSP frequencies
were registered. Data shows a sever reduction in inhibitory drive that lead to decrease
in connectivity and inhibition of pyramidal cells. This phenomenon is somewhat
rationalized by an anomalous synaptic vesicle cycling (Wallace et al. 2012).
A great body of literature indicates that strength of synaptic transmission
correlates with the overall state of neuronal physiology. Empirical evidence
demonstrates that loss of Ube3a negatively impacts dendritic arborization as well as
dendritic spine number in the hippocampus and visual cortex. The latter could be
connected to the increased levels of Ube3a substrates, specifically Ephexin 5. Ephexin
5, a RhoA guanine nucleotide exchange factor is involved in the suppression of
excitatory synapse number during development. In AS, decreases in the degradation of
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Ephexin 5 due to the loss of Ube3a function promotes greater synapse elimination
during development leading to a reduced number of synapses in the adulthood. In
addition to the impaired neuronal morphology, altered active and passive intrinsic
membrane properties and increased axon initial segments (AIS) were observed in
Ube3a m-/p+ mice. These changes could be ascribed to the elevated levels α1 subunit
of α Na/K ATPase (α1-NaKA), the voltage-gated sodium channel NaV1.6, and the AIS
protein ankyrin-G. Interestingly, genetic decrease of α1-NaKA protein levels through
genetic double crosses can rescue some of the behavioral and electrophysiological AS
phenotype leading us to believe that defective neuronal physiology underlies some of
the abnormal AS cognition.

1.8 Ube3a and activity-dependent plasticity
One of the remarkable features of the mammalian brain is that it undergoes
continuous experience-driven remodeling of structure, composition and number of
synapses. Extensive research shows that general alterations in synaptic plasticity or
accumulation of Ube3a-dependent proteins are probable causes of AS. However, a
possibility that AS may originate from the abnormal activity-dependent signaling is a
provoking thought.
Several reports challenge a long standing statute of Ube3a as a ―housekeeping
protein‖. First, Ube3a was proposed to have an important place in experience-driven
maturation of excitatory synapses in visual cortex. It was later shown that Ube3a
expression was found to fluctuate in response to synaptic activity in vivo and in vitro.
Particularly, Ube3a mRNA was elevated following glutamatergic receptor activation in
primary cultures and in vivo following exposure to a novel environment in behaving
animals. Subsequent identification of a novel Ube3a-interacting protein, activity
regulated cytoskeleton associated protein (Arc) provided some explanation to why the
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activated neurons may have to modulate Ube3a transcription. Arc is a well-studied
immediate early gene that undergoes rapid translation within first few minutes after
neuronal stimulation. However, the up-regulation of Arc is short-lasting and tightly
controlled by UPS. It is not unreasonable to hypothesize that an activity–driven increase
in Ube3a expression is one of the regulatory mechanisms to ensure that basal levels of
Ube3a substrates including Arc are restored. Under normal conditions, alterations in Arc
expression allow appropriate synaptic remodeling by influencing the surface α-amino-3hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPAR) distribution. In the case of
AS, chronically elevated Arc promotes increase in internalized GluR1 subunit; thus,
negatively affecting APMAR current and the number of silent synapses. It is not known if
the activity-dependent Arc expression and AMPAR endocytosis are regulated by Ube3a.
Further experiments are required to investigate these molecular processes during
neuronal firing.
In summary, it stands to reason that Ube3a may be involved in modulating
pathways that are involved in synaptic plasticity. This may explain why earlier work
investigating kinase alterations in the Ube3a maternal deficient mouse only revealed an
alteration in alpha-CaMKII phosphorylation. This data was collected under basal
condition. It is possible that more alterations in kinase phosphorylation, protein
degradation or receptor trafficking could be discovered by applying an activity-dependent
approach. The observation that total Ube3a expression exhibits experience-driven
patterns brought a new angle to AS research. Unfortunately, many questions still remain
unanswered.

1.9 Ube3a and other neurological disorders
Individuals with AS share several symptoms with other neurodevelopmental
disorders such as Rett and Fragile X Mental Retardation Syndrome (FXS). According to
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Table 1.1 Neurodevelopmental disorders with high penetrance of autistic features.
Angelman Syndrome

Rett Syndrome

Fragile X Syndrome

severe

variable

variable

absent
excessive laughter,
hyperactivity

loss of spoken language

variable
Hyperactivity, irritability

severe
decrease myelination,
abnormal brain
architecture

excessive laughter
gait abnormalities,
loss of hand use
reduced volume, white
matter impairment,
static encephalopathy

mild
eosinophilic, intranuclear
inclusions in neurons and
astrocytes

present

present

present

40-60%

20%-50%

1:12000- 1:20000
Ube3a
mutations/deletions

1:10000

18%-33%
1:4000 females; 1:8000
males

MeCP2 mutations

Fmr1 mutations

Ubiquitinaltion

Transcription regulation

Translation

hypoactivity (males)
decrease in motor
learning

hyperactivity

HUMAN
Intellectual disability
Communication
speech
Social interaction/
activity
Motor dysfunction

Brain abnormality
Seizures
Prevalence of ASD
features
Prevalence
Genetic deficits
Molecular
mechanism

MOUSE MODEL
hypoactivity, ataxic gate,
decrease in motor
Locomotor behavior
learning
Anxiety
Audiogenic
seizures

normal

increased

decreased

present

present

present

Social interaction

normal

impaired

abnormal

Autistic behaviors

Cognition

absent
absent
inflexibility in learning
poor performance in
poor performance in
poor performance in fear
hippocampal-dependent hippocampal-dependent conditioning , radial water
tasks
tasks
maze
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AS diagnostic criteria only cytogenetic analysis could definitely determine true AS cases.
The presence of impaired social interaction and communication, repetitive behavior,
seizures and intellectual disability places AS within ASD. Interestingly, some of the
disorders may also have an overlapping pathology. For example, the animal models of
FXS (Fmr1 KO) and AS are characterized by the cognitive impairments, audiogenic
seizures, abnormal synapse number and deficits in synaptic plasticity. Despite the
various molecular defects, these conditions may converge on the same biochemical
pathway that includes Arc. Both, Ube3a m-/p+ and Fmr1 KO have abnormally increased
Arc levels and subsequent alteration in AMPAR endocytosis. Although, the anomalous
Arc expression is a result of two distinct mechanisms: increased translation in Fmr1 KO
and decreased degradation in AS, there is a chance that similar downstream of Arc
changes could take place in both conditions. If it holds true, some of the hallmark deficits
in synaptic transmission observed in Frm1 KO mice should also be found in Ube3a
deficient animals. At the present moment, no data is available to support this hypothesis.
Recently, we have reported that treatment used in FXS clinical trial showed promising
results in AS patients. This may imply that common dysfunctions appear in both
syndromes.

In

conclusion,

regardless

of

the

genetic

mechanisms,

many

neurodevelopmental disorders share common pathology; thus, it is important to
incorporate knowledge obtained from other disease models to AS research in order to
aid an efficient exploration for potential therapeutics.
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CHAPTER 2: ACTIVITY-DEPENDENT CHANGES IN MAPK ACTIVATION IN THE
ANGELMAN SYNDROME MOUSE MODEL1

2.1 Abstract
Angelman Syndrome (AS) is a devastating neurological disorder caused by
disruption of the maternal UBE3A gene. Ube3a protein is identified as an E3 ubiquitin
ligase that shows neuron-specific imprinting. Despite extensive research evaluating the
localization and basal expression profiles of Ube3a in mouse models, the molecular
mechanisms whereby Ube3a deficiency results in AS is enigmatic. Using in vitro and in
vivo systems we show dramatic changes in the expression of Ube3a following synaptic
activation. In primary neuronal culture, neuronal depolarization was found to increase
both nuclear and cytoplasmic Ube3a levels. Analogous up-regulation in maternal and
paternal Ube3a expression was observed in Ube3a-YFP reporter mice following fear
conditioning. Absence of Ube3a led to deficits in the activity-dependent ERK1/2
phosphorylation, which may contribute to reported deficits in synaptic plasticity and
cognitive function in AS mice. Taken together, our findings provide novel insight into the
regulation of Ube3a by synaptic activity and its potential role in kinase regulation.

2.2 Introduction
Angelman syndrome (AS) is a neurological disorder that affects approximately
1:12,000 children (Steffenburg et al. 1996) and is characterized by severe

1

Portions of these results have been previously published (Filonova I, 2014) and are utilized with
permission of the publisher.
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developmental delay, cognitive disruption, absence of speech, contagiously happy
demeanor, ataxia, and a greater propensity for seizures (Pelc et al. 2008; Dagli et al.
2011). Absence, mutation or disruption of the maternal UBE3A allele results in a near
complete absence of protein expression in the central nervous system (CNS). UBE3A
encodes an E3 ubiquitin ligase (E6-AP) that shows neuron-specific paternal imprinting in
humans and mice (Jiang et al. 1998; Gustin et al. 2010; Daily et al. 2012). Ube3a has
few identified biochemical targets including activity-regulated cytoskeleton-associated
protein (Arc) and Ephexin 5 (Greer et al. 2010; Margolis et al. 2010); however, Ube3a is
likely to play multiple roles in the neuron and no single target of Ube3a fully explains the
unique phenotype associated with the disorder.
A recent study by Greer et al (2010) demonstrated dynamic expression of Ube3a
during synaptic activity. Specifically, Ube3a mRNA was significantly increased in
response to membrane depolarization or glutamate receptor activation in cultured
primary neurons. In addition, Ube3a expression was up-regulated in the mouse brain
during kainate-induced seizures and in response to enhanced environmental stimuli
during the novel object exploration test (Greer et al. 2010). Stringent control of Ube3a
expression is necessary for neuronal functioning. A prime example of this is human
UBE3A gene dosage. Absence of UBE3A results in AS, while the interstitial duplication
of UBE3A is associated with autism spectrum disorders (ASD) (Schanen 2006).
Supportive observations are made in mice lacking Ube3a and those with a Ube3a
duplication, both of which partially phenocopy aspects of AS and ASD, respectively.
Maternal Ube3a deficient animals show impaired locomotor activity, enhanced seizure
propensity and deficits in associative and spatial learning and memory (Jiang et al.
1998). Conversely, duplication of Ube3a results in poor social interaction, behavioral
inflexibility, and anxiety (Smith et al. 2011). Taken together, these data suggest that
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there is a critical homeostatic level of Ube3a expression that must be maintained for
normal neuronal function.
In the present study, we evaluate changes in Ube3a expression in response to
neuronal depolarization in vitro and neuronal activity in vivo. We present evidence that
control of Ube3a expression is critical for activity-dependent kinase activation. These
results better define the role of Ube3a in normal synaptic function in the CNS, expand
our knowledge about the paternal Ube3a protein expression, and examine
consequences of Ube3a absence in the context of neuronal activity.

2.3. Materials and Methods
2.3.1 Animals and reagents:

Animals: All animals utilized in the experiments were

handled in accordance with protocols approved by the Institutional Animal Care and Use
Committee of the University of South Florida. To generate paternally imprinted Ube3aYFP, C57 females were bred to Ube3a-YFP males. Maternal Ube3a-YFP mutants were
obtained by the opposite crosses. 3-3.5 months old pUbe3a-YFP males and females
were used in fear conditioning experiments to establish Ube3a expressional profiles.
129SV/C57 hybrid Ube3a m+/p- and wild type littermates 2-4 months old were used to
assess p-ERK activation. Antibodies: E6-AP (Bethyl lab); actin, ERK1/2, p-ERK1/2,
MEK1/2, p-MEK1/2, Histone H3, HSP90 (Cell signaling); NeuN (Millipore), ApoER2
(Abcam). Chemicals: KCl (Sigma, P9549, 50 mM).
2.3.2 Fear conditioning and tissue collection. Paternal Ube3a-YFP mice were handled 5
min/day for 5 days in the room where fear conditioning training took place. On the day of
experiment, each animal was placed in a sound attenuation chamber (SAC) for 4.5 min:
after 3 minutes of habituation 3 0.5 mA shocks with 30 sec intervals were applied to a
floor grid. Mice were euthanized with isoflourine at 5 min, 15 min, 1 hr, 3 hr, 6 hr

29

following conditioning (three animals per group, males and females). Mouse brains were
removed and cortex and hippocampus were dissected in ice-cold PBS containing Halt
protease and phosphatase inhibitors Cocktail (Thermo Scientific, 78440). Dissected
tissue was frozen on dry ice and stored at -80º C until further processing. A control
group of mice was subjected to fear conditioning training and was tested 24 hours later.
Freezing behavior was recorded and scored by AnyMaze software.
2.3.3 Western Blot (WB): Frozen tissue and primary neuronal cultures were
homogenized by sonication in ice-cold RIPA buffer buffer (50 mM Tris-HCl, pH 7.4, 150
mM NaCl, 2 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% triton X100)
containing Halt protease and phosphatase inhibitors cocktail. The lysates were clarified
at 22,000 g for 30 min. The protein concentrations were determined using the BCA
Protein Analysis Kit (Pierce, Rockford, IL). Samples were resolved by 10% TGX gels
(Bio-Rad) and transferred to PVDF membrane. Membranes were blocked with 5% milk
in TBST (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween-20) for 1 hour and
incubated with primary antibodies at 4ºC overnight. After 3 times 10 min washes with
TBST , secondary antibodies were applied for 1 hr at room temperature. Blots were
detected with film for chemiluminescence using Pierce ECL. Developed images were
analyzed using ImageJ software. Statistical analysis (Student t-test, ANOVA) was
performed using GraphPad Software.
2.3.4 Subcellular fractionation. Mouse brains and murine mixed primary neuronal
cultures were fractionated using the Subcellular Protein Fractionation Kit for Cultured
Cells (Thermo scientific, 78840) according to manufacture manual.
2.3.5 Primary neuronal culture: Mixed (cortical and hippocampal) cultures were used for
western blot analysis and subcellular fractionation. Brains from E16-E18 wild type 129Sv
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embryos were removed and dissected under microscope in ice-cold isotonic buffer (137
mM NaCl, 5.4 mM KCl, 170 μM Na2HPO4, 148 μM K2HPO4, 5.5 mM glucose, 58.4 mM
sucrose). Dissected tissue was pooled together in 15 mL tube and incubated with 1 mL
0.25% trypsin for 5 minutes at 37ºC. Trypsin was removed and 5 mL dissociation media
was added (DMEM, high glucose, 10% heat inactivate FBS, 1X antimycotic/antibacterial
solution). Hippocampi were dissociated by slowly pipetting through glass pipettes. After
brief

centrifugation, dissociation media was replaced by neurobasal medium

supplemented with 2% B27 and 0.5 mM glutamax. Cells were plated in 6 well
(2,500,000/ well) plates coated with poly-l-lysine. Cultures were treated with 55 mM KCl
on DIV 7-10.
2.3.6 Non-fluorescent Immunohistochemistry. Mice were transcardially-perfused with
saline solution (0.9% NaCl in water) followed by 4% PFA diluted in 0.1M PBS. Removed
brains were dehydrated via sucrose gradient (10%, 20%, 30%) and sectioned on a
cryostat at 30μm. Free-floating sections were blocked in 4% goat serum, 0.2% lysine in
0.1 M PBS and incubated with Ube3a primary antibody overnight (1:1000).
Secondary antibody were added for 2 hours and the avidin-biotin-HRP complex was
formed with VECTASTAIN® ABC kit (Vector labs). DAB was used to develop the stain.
Sections were imaged with a Zeiss Mirax Scan 150 microscope. Identification of positive
staining and percent area of positive stain was performed using Image Analysis software
(created by Andrew Lesniak, Zeiss, www.nearcyte.org).
2.3.7 Acute hippocampal slice preparation and treatment. 2 month old m-/p+ and m+/p+
littermates were sacrificed by decapitation, the brains were rapidly removed and briefly
submerged in ice-cold cutting solution (110 mM sucrose, 60 mM NaCl, 3 mM KCl, 1.25
mM NaH2PO4, 28 mM NaHCO3, 0.5 mM CaCl2, 5 mM Glucose, and 0.6 mM ascorbate)
saturated with 95% O2 and 5% CO2. Hippocampal slices (400 μm) were cut on a
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vibratome and allowed to equilibrate in artificial cerebrospinal fluid solution (125
mM NaCl, 2.5 mM KCl, 1.24 mM NaH2PO4, 25 mM NaHCO3, 10 mM Glucose, 2 mM
CaCl2, and 1 mM MgCl2) at 32ºC for 2 hours. Slices were treated with 55 mM KCl for 5
and 30 minutes, snap frozen and stored at -80ºC for further processing.

2.4 Results
2.4.1 Ube3a expression changes in primary neurons immediately after neuronal
depolarization.
Maternal Ube3a protein is present in the neuronal nucleus, soma and dendrites,
and is enriched in the postsynaptic compartment (Dindot et al. 2008; Gustin et al. 2010).
Subcellular fractionation was used to isolate soluble and non-soluble nuclear, membrane
and cytosolic compartments (Figure 2.1). To verify the specificity of the Ube3a antibody,
hippocampi from Ube3a deficient mice (Ube3a m-/p-) and littermate controls were
fractionated. The antibody shows specificity to Ube3a (approximately 110 kDa) with a
complete absence of reactivity in Ube3a m-/p- mice. We observed a single unidentified
protein band of a slightly higher molecular weight detected in the nuclear and chromatinbound fractions. We confirmed quality of fractions by detection of HSP90, ApoER2,
NeuN and histone H3 to the cytosolic, membrane, nuclear and chromatin-associated
fractions, respectively (Figure 2.1). Consistent with previous reports (Gustin et al. 2010),
we find that Ube3a is enriched in the cytosol with lower detection in the nucleus and
membrane compartments.
Next, we determined if synaptic depolarization could modulate Ube3a protein
expression in neuronal culture. Mixed primary cultures (DIV 8-10) prepared from E17-18
wild type brains were depolarized with 55 mM of KCl for 5 and 30 minutes. Western blot
analysis revealed that Ube3a expression following KCl treatment is significantly
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increased in the nucleus and cytosol as early as 5 minutes (nuclear soluble 201 ±
21.42%,*p<0.05; cytosol 153.5 ± 16.59%, *p<0.05) and remained elevated up to 30
minutes (nucleus 182.4 ± 34.78%, *p<0.05; cytosol 167.3 ± 17.51%, **p<0.01) (Figure
2.2 A-D). Ube3a was slightly down-regulated in the membrane fraction at 30 min;
however, the decrease failed to reach statistical significance. These data demonstrate
that KCl induced depolarization affects Ube3a protein levels resulting in increased
Ube3a expression in the cytosol and the nucleus.
2.4.2 Consequences of Ube3a absence on depolarization-induced kinase activation.
The wide variety and severity of AS symptoms suggests that the loss of Ube3a
causes a global disruption of synaptic function. This is supported in the AS mouse model
with identified synaptic disruption in the visual cortex, cerebellum and hippocampus
(Jiang et al. 1998; Heck et al. 2008; Yashiro et al. 2009). A multitude of Ca2+dependent signal transduction pathways are stimulated by synaptic depolarization.
Previously, basal levels of several kinases important for LTP induction and maintenance
in the hippocampus of AS mice were examined in the attempt to identify direct or indirect
targets of Ube3a ubiquitination. In this study, we sought to revisit the p44/p42
extracellular signal-regulated kinase (ERK1/2) and evaluate its response to neuronal
depolarization in wild type (Ube3a m+/p+) and Ube3a-deficient mice (Ube3a m-/p+). The
necessity of ERK p44/p42 (ERK1/2) is well established for synaptic plasticity and
memory formation (English and Sweatt 1997; Atkins et al. 1998; Thomas and Huganir
2004).
Acute hippocampal slices from Ube3a m-/p+ mice and wild type littermates were
treated with 55mM KCl for 5 or 30 minutes. Following Western blotting, the levels of total
and phosphorylated ERK1/2 (p-ERK, Thr202/Tyr204) and mitogen-activated kinase
kinase 1/2 (MEK1/2, p-MEK (Ser217/221)) were analyzed. Under basal conditions,
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Ube3a m+/p+ and Ube3a m-/p+ groups (n=6-7 slices, 3 animals per genotype) had
similar levels of total ERK1/2 and p-ERK (Figure 2.3 A, B). ERK1/2 activation was
determined by same blot p-ERK to total ERK ratio and standardized to non-treated
controls within genotype. All treated groups show elevated p-ERK after depolarization;
however, p-ERK levels in Ube3a m-/p+ slices (p-ERK1: 311 ± 20.83 %; p-ERK2: 207 ±
16.98%; **p<0.01, two-way ANOVA) failed to reach wild type levels (p-ERK1: 477.2 ±
57.65; p-ERK2: 354 ± 80%) at 5 minutes post depolarization (Figure 2.3 C and D).
Interestingly, levels were elevated from basal levels in both groups 30 minutes post
depolarization, but were not significantly different (n=6 per genotype). Basal expression,
phosphorylation and activation of MEK was not affected by the absence of Ube3a
(Figure 2.3 E and F). These data suggest that after neuronal depolarization only the
immediate activation of ERK is impaired.
2.4.3 Spatial and temporal properties of Ube3a expression following fear conditioning
training.
Next, we wanted to determine if similarities in the observed changes exist for
Ube3a and ERK1/2 in vivo. Recent reports suggest a dynamic regulation of Ube3a and a
close integration of this regulation with synaptic plasticity in wild type mouse brain (Greer
et al. 2010). The Ube3a allele is believed to show biallelic expression in all cell types,
with the exception of neurons. However, maternal deletion shows a near 100% absence
of Ube3a detection in the CNS (Figure 2.4 A-C). Increased Western blot exposure
reveals Ube3a protein that cannot be detected in the Ube3a m-/p- mouse brain (Figure
3). This observation raises the question of whether dynamic regulation of the paternal
allele is occurring, albeit at a reduced expression, or if the detection of protein is from
non-neuronal sources. Therefore, we sought to determine if both maternal and paternal
copies respond to neuronal activation. The heterozygous Ube3a-Yellow Fluorescent
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Protein (Ube3a-YFP) fusion protein reporter mouse allows the ability to distinguish
paternal from maternal protein expression by increasing the molecular weight of a single
allele with the addition of the YFP. Figure 2.5 C shows that paternal Ube3a-YFP is
resolved higher than maternal due to the presence of the 20 kD YFP tag. Using this
strategy, we next sought to determine if Ube3a protein changes could be detected with
in vivo synaptic activity following fear conditioned associative memory formation. Fear
conditioning (FC) was performed using a three foot-shock paradigm. To verify that this
training paradigm leads to robust memory formation, a separate group of paternal
Ube3a-YFP mice is shown to have a significant increase in freezing behavior compared
to a no shock, context only group (Figure 2.5 D). Western blot analysis of the whole
hippocampus and cortex collected at 5min, 15 min, 1hr, 3 hr and 6 hr intervals post
training revealed significant changes in maternal Ube3a expression in the hippocampus
(149.6 ± 14.68 %; *p<0.05) and cortex (378.4 ± 78.15 %; ***p<0.001) at 6 hr after FC
when compared to control group (Figure 2.6 4 A-D). Remarkably, paternal Ube3a was
significantly elevated only in hippocampus (1hr: 185.6 ± 15.82 %; 3 hr: 196 ± 14.05 %; 6
hr: 210 ± 19.65 %; **p<0.01) of pUbe3a-YFP mice starting at the 1 hour time point;
however, no similar response was observed in cortical samples (Figure 2.6 A-D). To
evaluate if exposure to the context could result in altered Ube3a expression, a group of
naïve mice (handled only) was examined and showed no difference (data not shown).
To determine if paternal Ube3a-YFP is affected by the inclusion of YFP, maternal
Ube3a-YFP animals were generated and Ube3a-YFP was compared to naïve Ube3a.
We found reduced maternal (86.6 ± 3.38 %; *p<0.05) or paternal Ube3a (56 ± 13.56 %;
**p<0.01) expression of the Ube3a-YFP fusion protein compared to naïve wild type
protein (Figure 2.5 A and B).
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Taken together our results suggest that both maternal and paternal alleles are
activated by synaptic activity. It appears that paternal Ube3a expression has a specific
temporal expression profile that is similar to the maternal activation in hippocampus, but
not in cortex. Paternal Ube3a comprises about 3-5% of total Ube3a in neurons; thus, the
amount of paternal protein increase is negligible. Nevertheless, it is critical to consider
and further characterize the paternal Ube3a allele, especially given the growing interest
in gene-based therapy approaches.
2.4.4 Activity-dependent p-ERK disregulation in Ube3a deficient mouse model.
Reduced ERK activation in response to neuronal stimulation may contribute to
the cognitive disruption present in Ube3a maternal deficient mice and human AS.
Numerous studies report that reduction in ERK activity disrupts associative fear
conditioned memory formation (Blum et al. 1999; Selcher et al. 2003). Next we
determined if hippocampal-dependent associative learning in adult Ube3a m-/p+ showed
reduced p-ERK activation in area CA1 following a 3 foot shock FC paradigm. This
experimental approach has previously shown increased ERK activation in area CA1 of
the hippocampus (Chwang et al. 2006). We subjected both Ube3a m+/p+ (n=5 control,
n=6 experimental) and Ube3a m-/p+ (n=5 for control, n=4 experimental) 3-4 month old
mice to FC and measured pERK levels in CA1 60 minutes after to FC training. No
significant change in total ERK1/2 or p-ERK1/2 was observed at baseline (Figure 2.7 B).
Significant differences in p-ERK activation became apparent when the samples were
compared at 60 minutes post training. Consistent with published data (Chwang et al.
2006) area CA1 of Ube3a m+/p+ hippocampi showed a significant increase in p-ERK2
levels (143.4 ± 14.19 % of Ube3a m+/p+, *p<0.05) compared to control group. By
comparison, p-ERK2 activation was blunted in Ube3a m-/p+ animals (82.10 ± 4.6 % of
Ube3a m-/p+ controls).
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(Figure 2.7 C). Analysis of CA3 and DG areas didn‘t reveal changes in total or p-ERK in
either wild type or in transgenic littermates (Figure 2.8 A-D).

2.5 Discussion
A preponderance of imprinted genes is associated with placental regulation and
represents a genetically unique method of regulating protein expression. However,
maternal Ube3a levels can undergo further regulation beyond paternal allele silencing.
For example, Ube3a is a target of itself, suggesting a negative feedback for regulating
protein level. This form of biochemical regulation may be in response to the recent
discovery of altered neuronal Ube3a expression following glutamatergic activation and
neuronal depolarization. A wide variety of activators including N-methyl-D-aspartate
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and brainderived neurotrophic factor (BDNF) can initiate an increase of Ube3a mRNA within 5
hours in primary cultures (Greer et al. 2010). In light of direct and indirect alterations of
Arc and CaMKII, both major players in synaptic plasticity, changes in Ube3a expression
suggests a role in synaptic function that supersedes the traditional roles of an E3
ubiquitin ligase. We sought to determine if Ube3a is altered in response to neuronal
depolarization and in vivo learning and memory. Furthermore, we wanted to investigate
if other signaling proteins modulated by calcium influx were likewise altered during
synaptic activity in the Angelman syndrome mouse model.
While we did not specifically delineate isoform expression, we find increased total
Ube3a in response to KCl treatment at 5 and 30 minutes post application in both
cytosolic and nuclear fractions isolated form primary neurons suggesting that this is not
an isoform-dependent phenomenon. Although ubiquitously-expressed, Ube3a localizes
to the nucleus where it serves as a transcriptional co-activator and plays a role in the
chromosome segregation (Nawaz et al. 1999; Singhmar and Kumar 2011). Nuclear
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association is also expected due to other Ube3a targets including p53, p27 or HHR23A
(Jiang et al. 1998; Kumar et al. 1999; Mishra and Jana 2008; Mishra et al. 2009).
However, the potential role for up-regulation of nuclear associated Ube3a is yet to be
determined. Greer and colleagues (2010) reported that Ube3a mRNA is up-regulated in
mouse hippocampus 1 hour following novel environment exploration task. In our study
we utilize the 3 foot shock fear conditioning paradigm to examine spatial and temporal
Ube3a changes in the paternal Ube3a-YFP reporter mouse brain. This particular model
allows quantification of both maternal and paternal proteins due to the differential
molecular weight of the paternal-derived Ube3a-YFP protein. Our results demonstrate
an increase in both maternal and paternal Ube3a expression starting at 1 hour post
training in hippocampus, while only maternal Ube3a expression is increased in the
cortex. The spatial differences in expression profiles may reflect the behavioral
paradigm, as fear conditioning is a hippocampal-dependent behavioral task requiring
extensive coordination of hippocampal pyramidal cell activity. Alternatively, the cortex
may represent a brain region where the imprinting center at 15q11 is much more tightly
regulated and the silencing mechanism is more stringent or insensitive to fear
conditioning. However, it is intriguing to find that neuronal activity might be sufficient to
overcome epigenetic silencing and allow, albeit modest, production of the paternal
Ube3a protein.
Identifying activity dependent regulation of Ube3a protein raises the possibility
that Ube3a is involved in activities other than housekeeping protein degradation. It
stands to reason that Ube3a may be involved in modulating pathways that are involved
in synaptic plasticity, and this may explain why our earlier work investigating kinase
alterations in the Ube3a maternal deficient mouse only revealed an alteration in alphaCaMKII phosphorylation (Weeber, 2003). Those previous experiments were performed
during basal conditions. The use of KCl-induced neuronal depolarization should
38

effectively activate multiple signaling pathways leading to ERK activation. Interestingly,
we demonstrate reduced phosphorylation of ERK in response to KCl depolarization in
the Ube3a m-/p+ mouse, suggesting that Ube3a is involved in a signaling cascade that
targets ERK phosphorylation. Curiously, we did not find a concurrent difference in either
total MEK or phospho-MEK levels, the kinase responsible for phosphorylation and
activation of ERK. This result may reflect a direct or indirect action of Ube3a on MEK‘s
ability to phosphorylate ERK or an Ube3a-dependent regulation of phosphatases. The
exact mechanism for this difference in ERK activation is currently under investigation.
There has been extensive investigation into the regulation of ERK in mice
performing various behavioral tasks. Depending on the learning paradigm, the p-ERK
levels are shown to increase as early as 1 minute post training and stay elevated for up
to 9 hrs (Blum et al. 1999; Chwang et al. 2006; Trifilieff et al. 2006; Trifilieff et al. 2007).
Both memory formation and hippocampal synaptic plasticity are sensitive to inhibition of
ERK activation and reduced p-ERK levels correlate nicely with deficits in memory
retention (Blum et al. 1999; Selcher et al. 1999). Our finding that p-ERK levels are
reduced following contextual fear conditioning in Ube3a m-/p+ mice provides an
additional rationale to explain the well-established associative learning deficit exhibited
by these mice (Jiang, 1998 ; van Woerden, 2007 ;Huang, 2013).
In conclusion, the present study suggests that Ube3a protein levels can change
significantly in response to neuronal depolarization, and importantly, during the
processes of associative learning and memory. Increased levels in both maternal and
paternal Ube3a are intriguing and raise important questions about regulatory
mechanisms of both maternal and paternal alleles. Furthermore, subtle changes in the
paternal Ube3a allele, its distribution, isoform production and function should be
addressed before considering it as a potential therapeutic target.
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Figure 2.1. Subcellular fractionation of a mouse brain. Subcellular fractionation
technique was used to isolate cellular fractions with minimal cross-contamination. CEBcytosolic, MEB–membrane, NEB–nuclear soluble, CRB–chromatin-bound.
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Figure 2.2. Ube3a expression changes in cytosol and nucleus following 55mM
KCl application. A and B. Representative western blot of Ube3a total protein increase
in cytosolic and nuclear fractions at 5 min (A) and 30 min (B) following 55mM KCl
stimulation in primary neuronal cultures (DIV 8-10). Ube3a is shown in 2 exposures
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western blot analysis (n=5, treatments standardized to NT group, one way ANOVA,
post hoc Tukey‘s test, *p<0.05, **p<0.01).

45

A

m+/p+

B

m-/p+

5’

NT

5’

30’

ERK1 / actin
ERK2 / actin

150

ERK / actin

p-ERK1/2

NT
30’

ERK1/2
p-MEK

100

50

MEK
acti
n

0
m+/p+

C
400

200

m-/p+

**

m+/p+
m-/p-

400
300
200

5

100
0

0
NT

5'

30'

NT

5'

NT

30'

E

5'

F

150

30'

NT

5'

30'

p-MEK1/2

800

p-MEK1/2 / MEK1/2

MEK / actin

m+/p+

ERK 2

500

m+/p+
m-/p+

*

pERK 2 / ERK 2

pERK 1/ ERK 1

D

ERK 1

600

m-/p+

100

50

m+/p+
m-/p+

600
400
200
0

0
m+/p+

NT

m-/p+

5'

30'

NT

5'

30'
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Quantitative Western blot analysis shows significantly decreased levels in pERK1/2
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(n=3) (one-way ANOVA, post hoc Tukey‘s test, *p<0.05).
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48

Figure 2.6. Changes in maternal and paternal Ube3a expression following
contextual fear conditioning. Paternal Ube3a-YFP mice received 3 shocks. mUbe3a
expression is elevated starting at 1hour and significantly increased in the hippocampus
(C) and cortex (D) of pUbe3a-YFP animals at 6 hr. pUbe3a-YFP is only increased in
hippocampus. All the time points are normalized and compared to ―context only‖ control
group (ctr). (n=3 per group; one-way ANOVA; Tukey‘s post hoc test; *p<0.05, **p<0.01,
***p<0.001).
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CHAPTER 3: MOLECULAR MECHANISMS UNDERLYING THE HIPPOCAMPAL
LTD IMPAIRMENT IN THE ANGELMAN SYNDROME MOUSE MODEL

3.1 Abstract
Long-term potentiation (LTP) and long-term depression (LTD) are the forms of
experience-driven synaptic plasticity that coexists in the brain. Protein degradation is
highly involved in both of these processes; thus, any alteration to the ubiquitin
proteasome pathways may lead to abnormal neuronal transmission. For example,
genetic deficits in UBE3A, E3-ligase that targets specific substrates for degradation
results in Angelman Syndrome (AS). Ube3a-deficient mice show an impaired
hippocampal LTP that corresponds to poor performance in hippocampal-dependent
behavioral tasks such as contextual fear conditioning and the hidden platform water
maze. Unfortunately, as much effort has been directed towards elucidating molecular
mechanisms underlying LTP defects, LTD has received little attention. In the present
study we have investigated the role of Ube3a in both hippocampal NMDAR-dependent
and NMDAR-independent LTD. We found that the magnitude of synaptic depression
was reduced in response to NMDAR and mGluR1/5 stimulations in AS mice.
Additionally, we examined mGluR1/5 signal transduction cascade to determine if any
changes in major pathway elements could explain the observed phenotype. No
alteration in mGluR1/5-induced kinase activation was detected; however, an abnormal
GluR2 distribution was observed. Our results suggest that Ube3a may play a greater
part in overall synaptic plasticity as it contributes not only to hippocampal LTP but also to
LTD expression.
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3.2 Introduction
Angelman syndrome (AS) is a rare childhood disorder with no preference to race,
ethnicity or gender. From an early age AS manifests as a delay of the major motor and
cognitive milestones, seizures, a complete absence of speech, excessive smiling and
laughter (Clayton-Smith and Laan 2003; Williams et al. 2006). AS is associated with the
UBE3A allele located on the imprinted region of 15q11-13 human chromosome (Kishino
et al. 1997; Matsuura et al. 1997). Maternal gene disruption through deletion, mutation,
unipaternal disomy or methylation defects results in nearly all cases of the disorder
(Lossie et al. 2001; Dagli et al. 2011). To date there are no accepted, specific treatment
for AS beyond standard therapy for seizure control.
The specific molecular role Ube3a may play in the process underlying the
cognition disruption is under active investigation. The UBE3A gene encodes an E3ubiquitin ligase that targets specific proteins for degradation and shows neuron-specific
paternal imprinting in humans and mice (Huibregtse et al. 1993; Scheffner et al. 1993;
Jiang et al. 1998; Gustin et al. 2010; Daily et al. 2012). The accumulation of Ube3a
substrates, produced by the Ube3a loss, is considered the main cause of the AS
pathology (Mabb et al. 2011). Several transgenic mouse models are currently available
to study Ube3a localization, function, and contribution in synaptic plasticity (Jiang et al.
1998; Miura et al. 2002; Dindot et al. 2008; Jiang et al. 2010). Ube3a deficient animals
nicely recapitulate some of the AS phenotype observed in humans. Beyond this, the
murine model produced through a null mutation of the maternal Ube3a exhibits
impairment in long-term potentiation (LTP) that may translate into poor performance in
hippocampal-dependent behavioral tasks such as contextual fear conditioning and the
hidden platform water maze (Jiang et al. 1998). Interestingly, the synaptic plasticity and
learning and memory defects can be reversed by genetic or protein replacement
manipulations (van Woerden et al. 2007; Daily et al. 2011; Kaphzan et al. 2013).
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The majority of literature examining synaptic function in the AS mouse model
has focused on the mechanisms responsible for the LTP deficit. Several hypotheses
have been proposed to address the decrease in excitatory synaptic transmission and
behavioral phenotype. Specifically, an aberrant CaMKII phosphorylation and reduced
activity-dependent ERK activation (Chapter 1) together with the altered phosphatase
activity have been suggested as potential mechanisms responsible for cognitive
disruption (Weeber et al. 2003). Additionally, accumulation of Ube3a substrates and
increased expression of a few proteins such as Arc and α1 subunit of Na/K ATPase
have been shown to contribute to the neuronal dysfunction (Greer et al. 2010; Kaphzan
et al. 2011; Kaphzan et al. 2013). While LTP is the most studied in vitro model of
learning and memory, it is not the only form of experience –driven synaptic plasticity that
exists in the brain (Malenka and Bear 2004). Long-term depression (LTD) represents a
different kind of long-term plasticity that elicits a variety of long-lasting changes through
the modification of synapses, promoting a long-lasting decrease in the strength and the
efficacy of the synaptic transmission. Electrophysiological data collected from the
maternal Ube3a-deficient animals demonstrate a necessity of Ube3a for excitatory
neuronal transmission; however, sparse evidence exists to assess the role of Ube3a in
LTD. A single study by Yashimo et al. reports that the absence of Ube3a leads to
biodirectional impairment in both LTP and LTD in the mouse visual cortex (Yashiro et al.
2009). The authors suggest that the deficit in the plasticity might be explained by an
increase of LTD induction threshold or possibly of an abnormal neurotransmitter release
caused by abnormal spine number. However, these possibilities are yet to be tested.
In present study, we focused on elucidating the role of Ube3a in hippocampal
LTD expression. We examined mGluR1/5 signal transduction cascade and AMPAR
expression to determine the molecular mechanisms underlying LTD deficits in Ube3a
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deficient mice. Our results suggest that altered synaptic depression may add to the
overall cognitive phenotype observed in AS mouse model.

3.3 Material and Methods
3.3.1 Animals: Animals utilized in the experiments were handled in accordance with
protocols approved by the Institutional Animal Care and Use Committee of the University
of South Florida. 129-Ube3a deficient mice were grouped and housed in a standard 12
hour light/dark cycle and fed mouse chow ad libitum.
3.3.2 Electrophysiology: 21-30 day old 129SVE Ube3a deficient (Ube3a m-/p+) and wild
type littermates (Ube3a m+/p+) were used to assess NMDAR – dependent (NMDARLTD) and NMDAR – independent LTD (mGluR-LTD). 6-8 week old animals were used to
investigate DHPG – induced LTD. Ube3a m-/p+ and Ube3a m+/p+ littermates (both
genders) were sacrificed by decapitation, the brains were rapidly removed and briefly
submerged in ice-cold cutting solution (110 mM sucrose, 60 mM NaCl, 3 mM KCl, 1.25
mM NaH2PO4, 28 mM NaHCO3, 0.5 mM CaCl2, 5 mM Glucose, and 0.6 mM ascorbate)
saturated with 95% O2 / 5% CO2. Hippocampal slices (400 μm) were cut on a vibratome
and allowed to equilibrate in artificial cerebrospinal fluid solution (ACSF) (124 mM NaCl,
5 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM Glucose, 2 mM CaCl2, and 1
mM MgCl2) at 30ºC for at least 2 hours prior to recording. The recording chamber was
maintained at 30º with ACSF flow rate at 1mL/min. Field excitatory postsynaptic
potentials (fEPSPs) were elicited via stimulation of Schaffer collaterals in the CA3
hippocampal area and recorded from stratum radiatum of CA1 via glass micropipettes
pulled to an approximate tip diameter of 1 μm (1–4 MΩ) and loaded with ACSF. The
delivery of stimulation was controlled by pClamp 9.0 software (Axon Instruments, Forster
City, California, USA), a Digidata 1322A interface (Axon Instruments), and stimulus
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isolator (model 2200, A-M Systems, Sequim, Washington, USA). All signals were
amplified using a differential amplifier (model 1800, A-M Systems), filtered at 1 kHz and
digitized at 10 kHz. Stimulus intensity was set to 50%-60% of the maximum fEPSP
response as determined from the input-output curve. The baseline responses were
collected every 30 seconds for 20 min. Input-output relationships were determined by
stimulating slices from 1-15 mV at 0.5 mV increments. Short-term plasticity was
measured via paired-pulse facilitation which was induced by stimulating slices sequential
pulses spaced at 20 ms intervals from 20-300 ms. NMDAR-LTD was induced by a PPLFS (paired-pulse low frequency stimulation) consisting of 900 pairs of stimuli (50-msec
interstimulus interval) delivered at 1Hz. mGlur-LTD was induced by the same PP-LFS
but in the presence of 50 µM D-AP5 (Tocris, 0805). DHPG-induced LTD was elicited by
a brief application of freshly made 100 µM (S)-3,5-DHPG (Tocris, 0805) diluted in room
temperature ACSF. For analysis, baseline slope was calculated from the mean slope
values recorded for 20 minutes before the PP-LFS or DHPG treatment. LTD values were
expressed as percentage of the fEPSPs standardized to baseline recordings. Statistical
analysis was performed for the last 30 minutes of recording following NMDAR-LTD and
DHPG-induced LTD, and 10-40 min post stimulation time interval for mGlur-LTD.
3.3.3 Acute slice preparation and drug treatment: 350 µm brain slices were prepared as
described above. After recovery at 30C for 2.5 hours slices, were treated with freshly
made 100 µM (S)-3,5-DHPG for 5 minutes. CA1 area was dissected under the
microscope at room temperature ACSF and flash frozen for further processing.
3.3.4 Western Blot: Frozen tissue was homogenized by sonication (3 pulses) in ice-cold
RIPA buffer (Thermo Scientific Pierce, # 89900) supplemented with 1X Halt protease
and phosphatase inhibitors cocktails (Thermo Scientific Pierce, # 78440). The lysates
were incubated on ice for 15 min and were clarified at 14,000 g for 15 min. The protein
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concentrations were determined using the BCA Protein Analysis Kit (Thermo Scientific
Pierce, 23227). Samples were resolved on 10% TGX gels (Bio-Rad) and transferred to
PVDF membrane. Membranes were blocked with 5% milk in TBST (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, and 0.1% Tween-20) for 1 hour and incubated with primary
antibodies at 4ºC overnight or 1 hr at room temperature. After 3 10 minutes washes with
TBST, secondary antibodies (Southern Biotech, 1:2000) were applied for 1 hour at room
temperature. Immunoreactivity was detected using Pierce ECL. Developed images were
analyzed by NIH ImageJ software. Statistical analysis (Student t-test, ANOVA) was
performed using GraphPad Software. Antibodies: E6-AP (Bethyl Biolabs; 1:2000), Arc (a
kind gift from Dr. Paul Worley; 1:200), β-actin (1:2000), p-ERK 1/2 (1:4000), ERK 1/2
(1:10000), p-mTor (1:2000), mTor (1:3000), p-p38 MAP (1:1000), p38 MAP (1:1000)
(Cell signaling).
3.3.5 Surface protein labeling: 350 µm brain slices were prepared as described above.
Slices were left at 30ºC to recover for 2 hours before surface biotinylation. EZ-Link SulfoNHS-LC-Biotin (Thermo Scientific Pierce, # 21335) was equilibrated to room
temperature and resuspended in cold ACSF at 1mg/mL. Slices were transfered to 1 mL
of the ice-cold ACSF-biotin solution and were incubated for 45 minutes at 4ºC while
slightly shaking. Tissue was washed once with ice-cold ACSF, once with 25mM Tris
(pH 8.1) to quench biotin, followed by 2 washed with ice cold 0.1M PBS (phosphate
buffer saline, pH 7.4). Slices were lysed with 70 µL of cold RIPA buffer (1X alt protease
and phosphatase inhibitors). Protein concentrations were determined with the BCA
Protein Analysis Kit and samples were adjusted to 1 mg/ml. 40 µg of protein was added
to 40 µL of NeutrAvidin Agarose beads (Thermo Scientific Piece, 29200) pre-washed 2
times with room temperature PBS, 1 time with RIPA buffer and incubated at 4ºC
overnight. Proteins were eluted with 35 µL of 2 X Lamelli buffer (Bio-Rad) at 95ºC for 10
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minutes. 4 µg of lysates and eluted samples were resolved on 4-15% TGX gels (BioRad). The ratio of surface expression to total expression was used to determine surface
levels of GluR1, GluR2. Antibody: GluR1, GluR2, mGlur1/5 (1:1000, Neuromab), NR2B
(1:2000; Millipore), β-actin (1:3000, Cell Signaling ), E6-AP (Bethyl Biolabs; 1:2000).
3.3.6 Hippocampal primary culture: Hippocampi from E16-E18 129SV/C57 embryos
were quickly dissected in ice-cold isotonic buffer (137 mM NaCl, 5.4 mM KCl, 170 μM
Na2HPO4, 148 μM K2HPO4, 5.5 mM glucose, 58.4 mM sucrose, briefly oxygenated with
95% O2 / 5% C02). Tissue was incubated with 0.25% trypsin for 5 min at 37ºC and
neurons were dissociated by titration. After brief centrifugation at 1500 rpm, cells were
resuspended in 2 ml of fresh Neurobasal media and plated on 13 mm poly-D-lysine and
laminin (Roche Applied Science, # 11243217001) pre-treated glass coverslips at 35,000
cells per well in 24 well plates. Cultures (DIV15-19) were stained for GluR1 and GluR2 to
determine basal levels of receptors internalization and activity-dependent endocytosis.
3.3.7 Immunocytochemistry: Internalized GluR1 and GluR2 staining. Low density
primary hippocampal cultures were labeled live with N-terminus antibodies against
GluR1 (Millipore, PC246; 1:15) and GluR2 (Millipore, MAB937; 1:75) for 20 min at 37ºC.
Cultures were rinsed with cold 100 mM PBS (pH 7.4) and exposed to 0.5 M NaCl/0.2
acetic acid (pH 3.5) for 4 min on ice to remove antibody bound to surface receptors.
Coverslips were washed with PBS and fixed with 4% PFA /4% sucrose for 15 min. Cells
were permeabilized with 0.1% Triton-X for 10 min and non-specific binding was blocked
with 10% goat serum, 0.1% BSA, 0.1% Triton-X for 1 hr. Internalized GluR1 and GluR2
were visualized with Alexa 488 or Alexa 546 secondary antibody (Invitrogen, 1:750).
Surface GluR1 and GluR2 staining. Neurons were labeled as described above. Media
containing antibody was removed and replaced with condition media containing 100 µM
DHPG or water. After 5 min incubation with the drug, media was exchanged and cells
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were allowed to incubate at 37ºC to promote AMPAR endocytosis. After 15 min, cultures
were fixed with 4% PFA /4% sucrose, blocked with 10% goat serum, 0.1% BSA, for 1 hr
and visualized with Alexa 488 or Alexa 546 secondary antibody (Invitrogen, 1:250).
Coverslips were imaged using the Olympus FV10i confocal microscope, 60X objective
(z-stack). For comparison between genotypes or drug treatment, images were taken with
the same exposure settings. Immunofluorescence of 3 dendrites per neuron was
analyzed. Images were thresholded, and pixel intensity of ROI was measured by NIH
ImageJ software.
3.3.8 .Statistical analysis: All data is shown as the mean ± S.E.M. Student‘s t-test and
ANOVA (Tukey‘s post hoc test) were applied as appropriate. Statistical significance was
determined when p < 0.05.

3.4 Results
3.4.1 Long-term depression is impaired in Ube3a m-/p+ mouse model
It has been widely accepted that the loss of Ube3a expression manifests in longterm potentiation (LTP) impairments (Jiang et al. 1998; Weeber et al. 2003; Yashiro et
al. 2009). Therefore, we sought to address if Ube3a also contributes to a different form
of synaptic plasticity such as hippocampal LTD. Hippocampal slices from young Ube3a
m-/p+ mice (n=5 animals) and their littermate controls (n=5 animals) were stimulated via
Schaffer collaterals in the CA3 area and the field excitatory postsynaptic potentials
(fEPSPs) were recorded extracellularly from stratum radiatum. To determine if Ube3a is
required for NMDAR-dependent LTD (NMDAR-LTD). Paired-pulse low frequency
stimulation (PP-LFS; 900 paired pulses (50 ms interstimuli intervals) 1Hz) was delivered
to Ube3a m-/p+ (n=8 slices, 4 animals) and wild type (n=9 slices, 4 animals)
hippocampal slices and the resulting fEPSP slopes were analyzed (Figure 3.1 A and B).
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PP-LFS induced depression of the fEPSPs in both genotypes; however, the Ube3a m/p+ mice displayed a significantly reduced synaptic response during the last 30 min of
recording (83.87 % ± 4.162 of the baseline; *p<0.0205) when compared to the Ube3a
m+/p+ littermates (67 % ± 4.669 of the baseline).
A great body of literature suggests that two forms of LTD, NMDAR-LTD and
mGluR-LTD, co-exist in the CA1 area of the hippocampus (Oliet et al. 1997; Bolshakov
et al. 2000). To differentiate between them, we initially applied the same PP-LFS
protocol but in the presence of 50 µM D-AP5 to eliminate the NMDAR component. A
significant decrease in fEPSP slope was observed in Ube3a m-/p+ slices (n=10 slices, 4
animals; 94.75 % ± 3.859 of the baseline; *p<0.0405) when compared to the wild type
controls (n=8 slices, 4 animals; 80.46 % ± 5.319 of the baseline) at the 10-40 min post
stimulation interval (Figure 3.2 A and B). mGlur-LTD could also be elicited by an acute
application of the selective mGluR1/5 agonist dihydroxyphenylglycine (DHPG) (Huber et
al. 2001). Thus, we decided to investigate the effect of DHPG on the fEPSP slope of the
Ube3a m-/p+ mice. As expected, a brief application of 100 µM DHPG triggered a
dramatic synaptic depression in both groups (Figure 3.2 C and D). Statistical analysis of
the last 30 min revealed that the magnitude of DHPG-induced LTD was significantly
decreased in the Ube3a m-/p+ mice (n=12 slices, 5 animals; 77.12 % ± 7.499 of the
baseline; *p<0.05) compared to the Ube3a m+/p+ littermates (n=13 slices, 5 animals;
57.46 % ± 3.895 of the baseline). Taken together, these data suggest a more general
function of Ube3a in long-term synaptic plasticity.
3.4.2 ERK 1/2 and mTOR activation is not affected by the loss of Ube3a
Our results indicate that Ube3a is crucial not only for LTP induction and
maintenance but also acts as an essential component of LTD expression. Next, we
decided to focus on the well-studied mGlur1/5 signal transduction cascade to determine
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if there are any alternations in the constitutive kinase expression and activation that may
contribute to the impaired mGluR-LTD found in Ube3a m-/p+ mice. Empirical evidence
demonstrate that mGluR-LTD requires de novo protein synthesis that heavily relies on
the activation of mitogen-activated protein kinases (MAPKs), such as p44/p42
extracellular signal-regulated kinase (ERK 1/2) and p38, and mammalian target of
rapamycin kinase (mTOR) (Gallagher et al. 2004; Hou and Klann 2004; Huang et al.
2004; Banko et al. 2006; Moult et al. 2008). These pathways are eventually connected to
the translation of mRNAs (Huber et al. 2000; Waung and Huber 2009). Initially, we
examined the basal levels of these kinases in the CA1 area of hippocampal slices
obtained from 4-6 week old Ube3a m-/p+ (n=12 slices, 4 animals) and the wild type
littermates (n=8 slices, 3 animals). Western blot analysis revealed no change in the
expression of ERK 1/2, mTOR or p38. (Figure 3.3 A and C). Additionally, no difference in
the phosphorylation state between the genotypes was observed (data not shown).
To ascertain that the kinase activation is not affected by the Ube3a absence, we
utilized the ability of DHPG to activate mGluRs and subsequently phosphorylate ERK
1/2 at Thr202/Tyr204, mTOR at Ser2448 and p38 at Thr180/Tyr182 residues. The
hippocampal slices were treated with 100 μM DHPG for 5 min and kinase activation was
determined by the same blot phospho-kinase to total kinase ratio and standardized to
non-treated controls within genotype. All treated groups show similar elevated levels of
p-ERK (Ube3a m+/p+: 266 % ± 40.23; Ube3a m-/p+: 261 % ± 18.66 of NT controls;
***p<0.001) and p-mTOR (Ube3a m+/p+: 138.6 % ± 12.4; Ube3a m-/p+: 164.6 % ±
21.56 of NT controls, *p<0.05) followed by DHPG application. Interestingly, activation of
p-p38 was not noted in any of the groups (Figure 3.3 B, D and E).
Our findings suggest that the mGluR-ERK 1/2 and mGluR-mTOR signaling is not
modulated by Ube3a. These data led us to believe that new protein synthesis is not
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affected in Ube3a m-/p+ mouse model. However, additional experimentation is needed
to solidify this assumption.
3.4.3 Arc expression is elevated in Ube3a m-/p+ CA3 area
Activation of mGluRs induces rapid local translation of several proteins that are
necessary for LTD expression (Waung and Huber 2009). One such ―LTD protein‖ Arc, is
shown to be regulated by Ube3a (Greer et al. 2010). To understand the involvement of
Arc in the mGluR-LTD deficit, we measured the total levels of this protein in the CA1
areas of Ube3a m-/p+ mice. Consistent with previously published data we observed a
significant increase in Arc expression (239 % ± 42.81 of Ube3a m+/p+ littermates,
*p<0.05) (Figure 3.4 B). Evidence suggests that Arc is actively translated in the response
to mGluR stimulation (Park et al. 2008; Waung et al. 2008); therefore, we determined
whether the DHPG-induced Arc dynamic is preserved under Ube3a-deficient conditions.
Surprisingly, we discovered a significant up-regulation after 5 min of 100 μM DHPG
application only in the Ube3a m-/p+ samples (n=12 slices, 200.5 % ± 27.71, *p<0.005),
but not in wild type littermate (n=8 slices, 147.4 % ± 44.73, p=0.35) (Figure 3 D and E).

3.4.4 Alternations in AMPAR subunits in Ube3a m-/p+ mice
Overexpression of Arc has been linked to the loss of surface AMPAR subunits.
As the dysregulation of GluR1 endocytosis has already been reported in the AS mouse
model, we sought to focus on Glur2 expression. Additionally, apart from GluR1, GluR2
subunits have been implicated in the mGluR-LTD (Zhou et al. 2011); therefore any
alteration in its expression may explain a reduction in mGluR-LTD observed in Ube3a m/p+ mice. To explore the consequences of elevated Arc on the basal GluR 2 abundance,
we utilized the receptor biotinylation technique. Results show the total expression of
GluR2 subunit (73 % ± 6.7 of Ube3a m+/p+ littermates, **p<0.01) was decreased in
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hippocampal lysate isolated from 4-6 weeks old Ube3a m-/p+ mice (n=7 slices, 3
animals) when compared to Ube3a m+/p+ controls (7 slices, 3 animals). No change was
detected in NR2B (Figure 3.5 A and B). The analysis of surface receptor expression
was achieved by normalizing biotinylated fraction to the total proteins within the same
sample. The quantification of surface proteins showed no change in NR2B and GluR1;
however, GluR2 levels were greatly reduced in Ube3a m-/p+ samples (63.3 % ± 8.8 of
Ube3a m+/p+ littermates, *p<0.05)
Based on our findings we sought to determine if a decrease surface receptors
levels would translate into an increased internal GluR2. We then measured the
abundance of internalized GluR2 (iGluR2) by immunocytochemistry. Live antibody
labeling and acid-strip approach has been successfully used to determine internal
AMPAR expression (Snyder et al. 2001). Using a similar method, we found that the
dendritic iGluR2 was significantly up-regulated in mature Ube3a m-/p+ hippocampal
cultures (n=15 cells; 115.4 ± 4.2, *p<0.05) compared to non-transgenic controls (n=15
cells) (Figure 3.5 C). Finally, we hypothesized that the altered levels of AMPAR would
block DHPG-induced GluR2 endocytosis. To test this empirically, mature hippocampal
cultures (DIV 15-18) were treated with 100 μM of DHPG and the surface GluR2 was
evaluated 15 minutes post stimulation (Figure 3.6 A and B). Surprisingly, a modest but
significant loss of GluR2 from the postsynaptic membrane was observed in both
genotypes (Ube3a m+/p+: n=23 cells, 91 % ± 1.3 of NT controls, ***p<0.001; n=20 cells,
93 % ± 1.9 of NT controls, *p<0.05). Our data suggests that while Ube3a loss influences
the total and surface levels of AMPAR, it does not affect the mGluR-mediated GluR2
trafficking.
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3.5 Discussion
LTP and LTD are forms of experience-driven synaptic plasticity. Despite using
distinct molecular and cellular mechanisms, neuronal potentiation and depression coexist in the brain (Oliet et al. 1997; Bolshakov et al. 2000). Similar molecular
mechanisms underlying LTP may also be involved in the mechanisms underlying
hippocampal-dependent learning and memory formation (Lynch 2004). However, a
behavioral correlate to the actions and mechanisms controlling LTD remain elusive
(Mukherjee and Manahan-Vaughan 2013). It is postulated that the balance between both
forms of synaptic plasticity is the foundation for healthy neuronal physiology. Thus,
human disorders with an associated cognitive defect may be caused by slight alterations
in signaling cascades that result in alterations in either LTP or LTD
The data presented here demonstrate that Ube3a m-/p+ animals display
pronounced LTD deficit in both NMDAR-dependent and NMDAR-independent forms in
the hippocampus. The observed reduction in NMDAR-LTD is not surprising and
consistent with the previous report of a decrease in LTD magnitude in the neocortex of
young and adult Ube3a m-/p+ animals (Yashiro et al. 2009). It is well established that
NMDAR-induced LTD relies on the activation of phosphatases, PP1 and calcineurin, to
modulate a wide variety of proteins involved in LTD propagation (Mulkey et al. 1993;
Kirkwood and Bear 1994; Mulkey et al. 1994). Additionally, CaMKII phosphorylation is
cited as one of the potential regulatory mechanisms of glutamatergic synaptic
depression (Schnabel et al. 1999; Mockett et al. 2011). Ube3a m-/p+ mutant mice
appeared to have deficits in both, PP1 activity and CaMKII autophosphorylation that
could partially explain the NMDAR-LTD phenotype (Weeber et al. 2003).
These studies also find that Ube3a is also involved in LTD elicited via Group I
mGluRs. In hippocampal slices, PP-LFS or a brief application of a selective mGluR 1/5
agonist failed to induce a similar LTD response in AS animals when compared to the
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wild type controls. It is well established that mGluR-LTD depends on the rapid protein
synthesis initiated by several intracellular signal transduction pathways including PI3K
and MAPK signaling cascades (Gallagher et al. 2004; Hou and Klann 2004; Banko et al.
2006). Interestingly, we have recently reported that ERK levels are unaltered in the adult
AS mouse; however, there are significant decreases in ERK activation following synaptic
depolarization and fear conditioning (Filonova et al. 2014). Interestingly, we find no such
alteration in ERK activation during depressive stimulation suggesting that this pathway is
not affected by the absence of Ube3a as we observe no changes in basal kinase
expression, phosphorylation or DHPG-induced activation.
Redistribution of AMPA receptors is the ultimate driving force of synaptic
transmission (Malinow and Malenka 2002; Song and Huganir 2002; Kessels and
Malinow 2009). Synaptic depression is facilitated by the reduction of post-synaptic
AMPA receptor subunits. In addition, rapid protein translation leads to up-regulation of
several LTD-related proteins required for activity-dependent AMPA receptor trafficking
(Waung and Huber 2009). One such protein is Arc, which is shown to be up-regulated in
the AS mouse model (Greer et al. 2010). It is unclear whether Arc is an immediate
Ube3a substrate (Kühnle et al. 2013); however, we also observe increased levels of Arc
protein in area CA1 of Ube3a m-/p+ hippocampal slices. Furthermore, using receptor
biotinylation and immunocytochemistry, we find a significantly reduced surface and
increased internal dendritic GluR2 expression in Ube3a m-/p+ hippocampus. This
observation is without a concurrent change in mGluR1/5 trafficking, indicating that the
initially compromised AMPA receptor distribution, but not aberrant receptor trafficking,
may underlie the deficit in mGluR-LTD.
Numerous studies report that Ube3a negatively impacts LTP and subsequently
disrupts learning and memory. We previously reported that saturating amounts of high
frequency stimulation results in synaptic plasticity equal to that in litter mate controls
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(Weeber et al. 2003). This suggests the capacity for plasticity in the hippocampus is
intact and the LTP defect induced with a standard 100Hz, two-train stimulation, is not
occluded. In other words, the measured synaptic activity is not already in a heightened
state of synaptic plasticity and ceiling effect for increased plasticity reveals itself as an
LTP defect. The results shown here suggest that the hippocampus of Ube3a m-/p+ mice
show an occlusion of LTD. If we consider that the total amount of plasticity, either toward
potentiation or depression, capable in area CA1 of Ube3a m-/p+ mice is equal to that of
littermate controls, then the increased Arc and subsequent decreased AMPAR would
have Ube3a m-/p+ mice starting at a base line already toward depression (Figure 3.7).
In conclusion, expanding our knowledge and studying Ube3a outside the context
of AS could not only prominently advance our understanding of this protein, but also
open a window of opportunities for finding potential therapeutics that are used to treat
other disorder to alleviate the severe cognitive symptoms associated with

the AS

patients.
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Figure 3.1 NMDAR-dependent LTD is impaired in AS mouse model. A and B.
NMDAR-LTD was induced by paired-pulse low frequency stimulation (PP-LFS) in Ube3a
m-/p+ (n=8, 4 animals) and Ube3a m+/p+ (n=9, 4 animals). Significant reduction was
observed during last 30 min of LTD recording (Student‘s t-test, *p<0.05).
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Figure 3.2. Ube3a m-/p+ animals show a deficit in mGluR-dependent LTD. A and B.
PP-LFS was delivered to hippocampal slices in the presence of 50 µM D-AP5 to induce
mGluR-dependent LTD. The induction of LTD (first 10 min) was not altered in Ube3a m/p+ (n=8, 4 animals) mice compared to Ube3a m+/p+ (n=10, 4 animals); however, the
analysis of the 10-40 min post stimulation time interval revealed a significant reduction in
fEPSP slope of Ube3a m+/p+ animals. C and D. mGluR-LTD was induced by a brief (5
min) application of 100 µM DHPG, a selective mGluR 1/5 agonist, in Ube3a m-/p+
(n=13, 4 animals) and Ube3a m+/p+ (n=12, 5 animals) mice. Significant reduction was
observed during last 30 min of LTD recording (Student‘s t-test, *p<0.05).
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Figure 3.3. mGluR-ERK 1/2 and mGluR-mTOR pathways are in the CA1 area of
Ube3a m-/p+ hippocampal slices.
A. Representative immunoblot of basal
expression of ERK 1/2, mTOR, MAPK p-38 (p38) kinases and their phosphorylated
states (p-ERK 1/2, p-mTOR, p-p38). Ube3a is used to indicate genotypes. C.
Constitutive levels of ERK 1/2, mTOR and and p38 are unchanged between the
genotypes (n=12 slices, 4 animals). Total protein levels are normalized to actin and
standardized to Ube3a m+/p+ controls (n=8 slices, 4 animals). B, D and E. mGluRtriggered ERK 1/2 and mTOR activation appears to be normal in the CA1 of Ube3a
m-/p+. Only Arc protein was statistically increased in Ube3a m-/p+ mice. (Student ttest, One-way-ANOVA were used when appropriate; ***p<0.001, *p<0.05).
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slices. A. mGlur1/5-triggered signal transduction pathways (Gladding, 2009). B. Basal
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when appropriate; *p<0.05).
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Figure 3.6. Ube3a is not required for DHPG-induced GluR2 endocytosis. A.
mGluR1/5 was activated by the application of 100 μM DHPG to induce AMPAR
internalization. Surface GluR2 was visualized by immunocytochemistry. B.
Immunoflourescence analysis of GluR2 intensity detected no difference in GluR2
trafficking between Ube3a m-/p+ (n=20 cells) and Ube3a m+/p+ (n=23 cells) mature
hippocampal cultures. (One-Way-ANOVA, *p<0.05, ***p<0.001).
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Figure 3.7. Altered basal state of the synapses results the inability of induce LTD
or LTP. Illustration of the potential for hippocampal plasticity for wild type (black) and AS
animals (red). AS mice have a non-stimulation base line potential below that of wild type
mice. This results in a lower percentage of DHPG- and low frequency stimulation-induced
LTD. High frequency stimulation (HFS) also results in a lower percentage increase
compared to wild type mice. Saturating high frequency stimulation (sHFS) results in the
same maximum amount of potentiation as wild types, but occurs with a greater
percentage increase between HFS and sHFS.
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CHAPTER 4: THE ROLE OF UBE3A IN FXS PATHOLOGY

4.1 Abstract
Substantial evidence suggests that the loss of Ube3a alters activity–dependent
signal transduction, which may ultimately result in impaired synaptic plasticity and
cognition. Similar to AS, abnormal molecular and behavioral phenotypes have been
observed in other mouse models of human mental retardation such as Fragile X Mental
Syndrome (FXS). Analogous to Ube3a deficient mice, Fmr1 KO mice exhibit learning
and memory deficits following contextual and trace fear conditioning which are paralleled
by cellular changes such as increased Arc expression and abnormal AMPAR
distribution. These data suggest that Ube3a and FMRP may belong to a similar signaling
pathway. In this work, we sought to explore if any of deviations in neuronal functioning
caused by FMRP loss-of-function could be due to the abnormal Ube3a expression.
Analysis of crude synaptoneurosomes of adult Fmr1 KO mice revealed a significant
reduction in Ube3a protein as well as blunted local translation of Ube3a following
mGluR1/5 stimulation. However, no evidence of direct association of Ube3a mRNA and
FMRP was found. To examine if some of the pathology seen in Fmr1 KO mice might
originate from Ube3a down-regulation, we performed a rescue experiment by increasing
Ube3a expression in the hippocampus of Fmr1 KO mice via AAV-mediated delivery. An
exhaustive battery of behavior testing revealed no significant effect of Ube3a on major
abnormal behaviors of the Fmr1 KO mice, with the exception of worsening already
impaired associative fear conditioning. These results suggest that while diminished level
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of Ube3a may contribute to subtle phenotypes observed in FMRP deficient mice, it is not
solely responsible for the FXS neuropathology.

4.2 Introduction
Autism spectrum disorder (ASD) comprise a family of developmental disorders
characterized by impaired social interaction and communication, stereotyped behaviors,
restricted interests, intellectual disabilities and often seizures (Tuchman and Rapin 2002;
Baird et al. 2006). The prevalence of ASD has been rising alarmingly over the last
decade (Wing and Potter 2002; Kogan et al. 2009; Matson and Kozlowski 2011).
Currently, almost 1:100 children who exhibit some of the warning signs are diagnosed
with ASD (Baird et al. 2006). A complex interaction of multiple genes and environmental
factors are thought to give rise to ASD (Abrahams and Geschwind 2008). The
complicated genetic aetiology creates an obstacle for identifying specific molecular
mechanisms that underlie the symptoms. There are several neurodevelopmental
disorders with high penetrance of autistic features such as Rett Syndrome, FXS (FXS)
and AS that allow dissecting out specific dysfunctional cellular processes present in the
disorder spectrum. The phenotypical overlap between these syndromes suggests that
the independent ASD candidate genes may occupy convergent molecular pathways.
FXS is the most common form of mental retardation (1:4000 males, 1:8000
females) with highly variable symptoms (Barth et al. 2004). Intellectual disability, speech
impairment, and abnormal social and emotional interactions are frequently observed in
FXS individuals (Hagerman and Hagerman 2002). Approximately 4% of the ASD
population has FXS related mutations indicating that anomalous molecular changes that
exist in FXS are also present in patients with autism (Rogers et al. 2001; Volkmar et al.
2005; Clifford et al. 2007). Most FXS cases originate from the hyper-expansion and
methylation of CGG repeats within the promoter of FMR1 gene (Fu et al. 1991; Verkerk
81

et al. 1991). FMR1 codes for fragile X mental retardation protein (FMRP), an mRNA
binding protein that is involved in activity-dependent translation (O'Donnell and Warren
2002). The loss of FMRP function leads to exaggerated translation (Qin et al. 2005;
Osterweil et al. 2010) culminating in abnormal spine morphology and number (Comery
et al. 1997; Irwin et al. 2000), defective synaptic plasticity (Mercaldo et al. 2009) and
poor cognition (Mineur et al. 2002; Zhao et al. 2005) . About 30% of the post-synaptic
neuronal mRNAs are thought to be regulated by FMRP (Darnell et al. 2011).
Interestingly, several FMRP targets such as CamKII α (Zalfa et al. 2003; Hou et al. 2006;
Muddashetty et al. 2007), Arc (Bassell and Warren 2008; Niere et al. 2012), PSD 95
(Todd et al. 2003) and GluR1 (Muddashetty et al. 2007) have also been implicated in AS
neuropathology (Weeber et al. 2003; Greer et al. 2010). Despite the distinct molecular
dysregulations responsible for these disorders some common symptomology is
observed between FXS and AS conditions in humans and mice (Table 1.1 and Table
4.1). For example, both Fmr1 KO and Ube3a m-/p+ transgenic animals have audiogenic
seizures and deficits in trace and contextual fear conditioning (Jiang et al. 1998; Zhao et
al. 2005; Huang et al. 2013). Moreover, increased Arc expression, alterations in AMPAR
distribution perturb regulation of CaMKII function may result from the loss of either
Ube3a or FMRP. These evidences suggest that Ube3a and FMRP may belong to a
convergent pathway important for learning and memory formation. A recent analysis of
discrete mRNA sequences that serve as a recognition sites for FMRP binding uncovered
almost 100 ASD-related genes. Electrophoretic mobility shift assays, microassay chip
and immunobloting were used to validate some of the novel FMRP targets including but
not limited to Ube3a and Sacsin (Ascano et al. 2012). This study was the first to propose
a potential molecular link between AS and FXS; however, more experimentation is
needed to establish a true connection.
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In this work we sought to elucidate if any of the cognitive deficits found in Fmr1
KO mice could be due to the alteration in Ube3a expression. We discovered a reduction
in synaptic Ube3a protein in the hippocampus of adult Fmr1 KOs. We utilized Ube3aAAV virus to deliver wild type Ube3a to the hippocampus of Fmr1 KO animals in order to
counteract the deficit in protein. A battery of behavioral testing showed that the addition
of exogenous Ube3a exacerbated the cognitive phenotype in this transgenic mouse
model. Overall, the data suggest that diminished level of Ube3a may contribute to the
FXS neuropathology.

4.3 Material and methods
4.3.1 Animals: All animals used in the study were handled in accordance with protocols
approved by the Institutional Animal Care and Use Committee of the University of South
Florida. Animals of either sex were group housed in a standard 12 hour light/dark cycle
and fed standard mouse chow ad libitum. Due to the X-link genetic FXS transmission,
only 3-4 months old Fmr1 KO males (FVB/129 SV mixed background) were used in
behavioral and biochemical assessments.
4.3.2 AAV-injections: Ube3a–AAV and GFP-AAV constructs were previously described
(Daily et al. 2011). Mice were anesthetized and placed in the stereotaxic apparatus
(51725D Digital Just for Mice Stereotaxic Instrument, Stoelting, Wood Dale, IL). The
following coordinates were used to locate hippocampus: AP -2.7 mm, L ±2.7 mm, and V
-3.0 mm. The Ube3a-AAV (1.5×1012 genomes/mL; n=8) or GFP-AAV (1.4×1012
genomes/mL; n=8) was delivered bilaterally via intrahippocampal injections using a 10
µL Hamilton syringe. Recombinant viral vectors in 1µL volume were co-administered
with 1 µL of 20% mannitol in each hemisphere. Singly housed mice were allowed 5
weeks recovery before the behavioral testing.
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4.3.3 Behavioral testing:
Elevated Plus Maze (EPM): The elevated plus maze (Stoelting, cat: 60140) was used to
assess anxiety. The EPM apparatus consisted of two enclosed and two well-lit open
arms that represented safe and fearful areas respectively. Each mouse was placed in
the center of the elevated plus maze and allowed 5 minutes of free exploration. Video
tracking software (Anymaze, Stielting) recorded mouse behavior and measured total
distance travelled, time immobile, time spent in each arm and total entries to open arms.
Open Field: Open field test was used to evaluate the animal‘s locomotor activity and
anxiety related behavior. Each mouse was placed in a box (40cm X 40 cm X 35 cm) and
allowed free exploration for 15 minutes. A moderate lighting was used above an open
field box as well as white noise to provide an even background. During the test, multiple
parameters (distance travelled, time spent in center and number of animal entries into a
center zone) were measured by video tracking software (ANY-maze).
Hidden platform water maze: The Morris Water Maze (MWM) was used to determine
spatial memory. A 1.2 m diameter pool was filled with white opaque water. A 10 cm
diameter white platform was submerged just below the water surface and large extramaze cues positioned around the room. Animals were placed in the pool and allowed to
swim to the platform for a maximum of 60 seconds. The training paradigm consisted of 4
trials/day for 4 days. Latency to escape and swim speed were measured by video
tracking software (ANY-Maze). On the 5th day, the platform was removed and a 60
seconds probe test was conducted.
Contextual Fear Conditioning: Fear conditioning was used to assess learning and
memory formation. On the day of training, animals were placed in a sound attenuated
chamber for 3 minutes. Then, a 30 second acoustic conditioned stimulus (70 dB sound)
was delivered with a 0.5-mA shock applied to the floor grid during the last 2 seconds of
the conditioned stimulus. Training consisted of two mild shocks paired with two
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conditioned stimuli with a 1.5 minute interval between each shock. For contextual
memory, the mice were placed in the same chamber 24 hours later and monitored for 3
minutes. Freezing behavior (2 seconds motionless position) was measured and percent
of time spent freezing was calculated.
Marble Burying Test: Marble burying test was used to evaluate anxiety, neophobia and
compulsive behaviors. A plastic cage (30cmX50cm) was filled with softwood bedding
(different from the regular home cage bedding). The surface was flattered and 15 glass
marbles were positioned evenly throughout the cage. The animal was placed in the cage
and allowed to explore for 30 minutes. After the animal was removed, the buried marbles
(2/3 covered with the bedding) were counted.
Social Interaction: Social interaction test was performed as previously described with
some modifications (Moy et al. 2004; Nadler et al. 2004). In short, the experimental
mouse was placed in the test cage and, after a 10 minutes habituation period (trial 1), a
new mouse was added to one side of the apparatus. The interaction between the test
mouse and the novel mouse was videotaped for 10 minutes (trial 2). The percent of time
spent in a quadrant with the novel mouse (social quadrant) was calculated using ANYmaze software.
4.4.4 Synaptoneurosome isolation: Crude synaptoneurosomes were prepared as
previously described (Villasana et al. 2006). Briefly, hippocampal tissue dissected from
adult Fmr1 KO (3-4 months) and wild type littermate brains was homogenized in 2 mL
dounce homogenizer with pestle A (5 strokes) and pestle B (5 strockes) in buffer
containing 10 mM HEPES, 1 mM EDTA, 2 mM EGTA, 0.5 mM DTT, protease and
phosphatase inhibitors. Samples were filtered 2 times through a 100 μm pore nylon filter
(Millipore) and 1 time through a 5 μm pore nylon filter using 5 mL Luer Lock syringe.
Some of the sample was set aside for the crude lysates analysis. The remaining filtrate
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was centrifuged at 1000g for 10 min at 4ºC. The pellet containing crude
synaptoneurosomes was resuspended in 0.32 M sucrose and 1 mM NaHCO3 (pH 7.0).
The sample concentration was determined with the BCA assay and stored at -80 ºC until
further processing.
4.4.5 Synaptoneurosomal stimulation. The procedure was done as previously reported
(Muddashetty et al. 2007). Cortical tissue was isolated from 3-4 months old wild type and
Fmr1 KO mice. Synaptoneurosomes were prepared as described above but using a
different homogenizing buffer: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2.5 mM
CaCl2, 1.53 mM KH2PO4, 212.7 mM glucose, and 1 mM DTT, pH 7.4, supplemented
with protease inhibitors, 30 U/ml human placental RNase inhibitor and 200 g/ml
chloramphenicol (Sigma, St. Louis, MO). After the centrifugation step, the pellets were
resuspended in the same buffer to 1 µg/μl. Triplicate samples (60µl volume) were
incubated for 15 minutes at 37ºC in the presence of a vehicle or 1 mM MCPG before the
addition of 30 µM DHPG for 30 min. At the end of the experiment, samples were frozen
with dry ice and stored in -80ºC until western blot analysis.
4.4.6 Western Blot: Frozen tissue was homogenized by sonication in ice-cold RIPA
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 0.5% sodium
deoxycholate, 1% triton X100) containing Halt protease and phosphatase inhibitors
cocktails. The lysates were clarified at 14,000 g for 15 minutes. The protein
concentrations were determined using the BCA Protein Analysis Kit (Pierce, Rockford,
IL). Samples were resolved by 10% TGX gels (Bio-Rad) and transferred to PVDF
membrane. Membranes were blocked with 5% milk in TBST (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, and 0.05% Tween-20) for 1 hour and incubated with primary antibodies at
4ºC overnight or 1 hour at room temperature. After 3 10 minutes washes with TBST,
secondary antibodies were applied for 1 hour at room temperature. Blots were detected
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with film for chemiluminescence using Pierce ECL. Developed images were analyzed
using ImageJ software. Antibodies: Ube3a (Bethyl BioLabs), PSD 95 (Neuromab),
FMRP (Millipore), β-tubulin (Cell Signaling).
4.4.7 Non-fluorescent immunohistochemistry: Mice were transcardially-perfused with
saline solution (0.9% NaCl in water). Removed brains were placed in 4% PFA diluted in
0.1M PBS and dehydrated via sucrose gradient (10%, 20%, 30%) and sectioned on a
microtome at 30 μm. Free-floating sections were blocked in 4% goat serum, 0.2% lysine
in 0.1M PBS and incubated with Ube3a primary antibody overnight (1:1000). Secondary
antibodies were added for 2 hours and the avidin-bionit-HRP complex was formed with
VECTASTAIN® ABC kit (Vector labs). DAB was used to develop the stain. Sections
were imaged with a Zeiss Mirax Scan 150 microscope. Identification of positive staining
and percent area of positive stain was performed using Image Analysis software
(created by Andrew Lesniak, Zeiss).
4.4.8 Statistical analysis: One-way ANOVA (Tukey‘s post hoc test) or Student t-test was
applied when appropriate using Graph Pad Prism 5.01 (La Jolla, CA).

4.4 Results
4.4.1 Synaptic Ube3a expression is decreased in the hippocampus of adult Fmr1 KO
mice
Ube3a is ubiquitously expressed throughout the neuron. It is also present in the
synaptoneurosomes and PSD fraction (Dindot et al. 2008; Gustin et al. 2010). Our early
results demonstrated that Ube3a expression is crucial for the mGluR1/5-dependent LTD
(Chapter 3), a form of synaptic plasticity that heavily relies on local protein synthesis and
that is under the control of FMRP repressor protein. Additionally, the observations that
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both AS and FXS share some common features led us to hypothesize that some of the
FXS pathology might be due to the alterations in Ube3a expression. To address this
question, we examined total Ube3a levels in the hippocampus of adult Fmr1 KO mice via
immunochistochemistry (3-4 months old, n=8 per genotype). We detected no differences
in Ube3a staining between Fmr1 KO and the littermate controls (Figure 4.1 A and B).
Data shows that FMRP is localized to the dendrites where it regulates translation of a
specific group of proteins. Therefore, we utilized a subcellular fractionation technique to
study Ube3a expression in isolated crude synaptoneurosomes. The filtration method
allowed us to obtain fairly pure synaptoneurosomes as we found an enrichment of PSD
95 and synaptophysin in the synaptoneurosomal fraction compared to the crude lysates
(Figure 4.2 A). Using western blotting, we found a significant reduction in synaptic
Ube3a expression in Fmr1 KO mice (64.43 % ± 7.630 of WT controls, n=4) compared to
the wild type controls (100% ± 7.872, n=5). Consistent with previous publications,
(Muddashetty et al. 2007), we also detected a reduction in PSD 95 and GluR1 proteins.
(PSD 95, 59.44 % ± 7.191; GluR1, 59.21 % ± 5.012 of WT controls). FMRP antibody
served as a positive control for correct genotyping (Figure 4.1 C and D). The changes
detected in Ube3a suggest a possibility of an interaction between these two proteins.
4.4.2 Synaptic Ube3a expression induced by mGluR1/5 stimulation is blunted in Fmr1
KO mice
It has been widely accepted that the null mutation of Fmr1 leads to the enhanced
mGluR-LTD suggesting that FMRP is crucial for the mGluR signaling (Huber et al. 2002;
Koekkoek et al. 2005; Hou et al. 2006). Several FMRP targets such as PSD 95
(Muddashetty et al. 2007), Arc (Niere et al. 2012) and STEP (Zhang et al. 2008) show an
increase in local protein synthesis in response to mGluR1/5 activation by DHPG. To test
if Ube3a is also subjected to similar regulation, we stimulated crude synaptoneurosomes
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isolated from the wild type cortex with 30 μM DHPG for 5 min, 30 min and 45 min and
used western blotting to determine Ube3a levels. We observed a significant increase in
Ube3a (157.9 % ± 11.40 of NT controls, n=8) as well as PSD 95 (136.1% ± 9.682 of NT
controls, n=6) following by 30 minutes DHPG application. Tubulin expression was not
affected. To ensure that the increase in protein levels was due to the mGluR1/5
activation, we pretreated synaptoneurosomes with 1 mM of MCPG, a mGluR antagonist.
No significant changes in neither Ube3a nor PSD 95 were detected in MCPG-treated
samples (Ube3a, 120% ± 11.55; PSD 95, 105.7% ± 4.655 of NT controls, n=3) indicating
that the observed elevation in Ube3a and PSD 95 is mGluR1/5 specific. Next, we
investigated if increase in Ube3a following mGluR1/5 stimulation is intact in the FMRP
deficient mice. Thus, we performed synaptoneurosomal stimulation in the cortex of Fmr1
KO transgenic littermates. The previously observed increase in Ube3a protein in
response to DHPG application was abolished in FMR1 KO cortical synaptoneurosomes.
These results provided more evidence for the potential regulation of Ube3a by FMRP.
Finally, we proceeded to determine if Ube3a mRNA directly binds FMRP protein by
performing direct FMRP IP and subsequent RNA analysis. We did not find an interaction
between FMRP and Ube3a mRNA suggesting that the decrease in Ube3a expression in
Fmr1 KO mice is a product of other molecular abnormalities cause by the FMRP loss.
4.4.3. Increase in exogenous Ube3a protein exacerbates behavioral phenotype of Fmr1
KO mice
Fmr1 KOs exhibit a variety of abnormal behaviors such as increased anxiety
(Spencer et al. 2005), aberrant social interaction (Mineur et al. 2006; McNaughton et al.
2008), hyperactivity (Mineur et al. 2002) and decreased freezing rates in contextual and
trace fear conditioning tests (Paradee et al. 1999; Zhao et al. 2005). Despite the
absence of the direct interaction between FMRP and Ube3a, we hypothesized that
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Ube3a might partially contribute to the neuropathology seen in Fmr1 KO mice. To test
this, we increased Ube3a expression via AAV-mediated delivery of exogenous Ube3a,
which we have previously shown to ameliorate synaptic and behavioral deficits in the AS
mouse model (Daily et al. 2011). Then, we investigated if any of the abnormal
phenotypes could be rescued by the increase of wild type Ube3a to the hippocampus of
Fmr1 KOs.
To determine the effect of the increased Ube3a on the Fmr1 KO behavior
phenotype, we injected adult (3-4 month old) FMRP deficient males with Ube3a-AAV or
GFP-AAV control vector and conducted a battery of behavioral tests 5 weeks following
the injection. To start with, we examined the anxiety-related behaviors by subjecting
mice to the elevated plus maze test (EPM). No difference was observed in time spent in
the open arms when comparing either genotypes or experimental groups (Fmr1 KO +
Ube3a-AAV and Fmr1 KO + GFP-AAV). However, we detected statistically significant
genotypic difference between wild type (19.24 ± 2.669, n=7, *p>0.05) and Fmr1 KO +
GFP-AAV (7.138 ± 1.772) in immobile time but not between Fmr1 KO + Ube3a-AAV
(Figure 4.3 A-C). These data demonstrate that increasing Ube3a expression does not
affect anxiety in Fmr1 KO mice.
Next, the general activity and locomotor behavior was evaluated by 15 minute
exposure to an open field. In accordance with previous publications, we found a
significant increase in distance traveled in both experimental groups (Fmr1 KO + Ube3aAAV, 40.38 ± 1.217; Fmr1 KO + GFP-AAV, 39.33 ± 3.144, **p>0.01) compared to WT
controls (26.60 ± 2.770) (Figure 4.4 A). Analysis of center entries didn‘t indicate any
dissimilarity between the groups; however, a trend toward increased center occupancy
was observed in Fmr1 KO + Ube3a-AAV animals (Figure 4.4 B and C). Additionally, a
social interaction test and a marble burying test were used to examine social deficits and
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compulsive behaviors and neophobia, respectively. All the groups performed evenly well
on both tasks (Figure 4.6 A-B).
Spatial learning and memory was tested by using the hidden platform water
maze test. All the groups were trained for 4 days (4 trials a day) to find the hidden
platform. The latencies to reach the platform were similar in all the animals indicating
comparable to the wild type memory acquisition in Fmr1 KO + Ube3a-AAV and Fmr1 KO
+ GFP-AAV groups. A 60 second probe trial was conducted on the 5th day of testing
revealed no difference in the time spent in the target quadrant, suggesting that all the
animals could equally remember the location of the escape platform. The occupancy
plots indicate the utilization of similar strategies by all groups (Figure 4.5 B and C).
A separate hippocampus-dependent task, contextual fear conditioning, was used
to evaluate learning and memory through freezing behavior in the context 24 hours after
training. Fmr1 KO + Ube3a-AAV (6.619 % ± 1.192 of total time freezing, ***p>0.001) and
Fmr1 KO + GFP-AAV (14.10% ± 2.471, p>0.01) animals showed significantly lower
freezing rates compared to the wild type (32.31 % ± 4.551) (Figure 4.5 A). Interestingly,
a significant reduction was detected in Fmr1 KO injected with Ube3a-AAV compared to
the Fmr1 KO + GFP-AAV suggesting that the increase in Ube3a negatively influenced
contextual fear memory.
4.4.4 Ube3a-AAV expression in Ube3a m-/p+ and Fmr1 KO
Initially, we tested the efficacy of the viral delivery, distribution and the ability to
express the protein of Ube3a-AAV construct in Ube3a m-/p+ (Daily et al. 2011). This
mouse model produces small (approximately 5% of total) paternal Ube3a allowing for
easy differentiation between endogenous vs exogenous Ube3a expression. Ube3a m/p+ mice were injected intrahippocampally with either Ube3a-AAV (n=4) and GFP-AAV
(n=3) and were sacrificed 5 weeks post-surgery. Ube3a and GFP expressions were
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assessed by immunohistochemistry (Figure 4.7 A). We observed an increase and wide
distribution of Ube3a and GFP expression. Next, we examined the Ube3a-AAV
expression in the Fmr1 KOs that were used in the behavior testing. We found that the
Ube3a expression was statistically increased in Fmr1 KO+Ube3a-AAV group (n=4;145.2
% ± 13.9 of the wild type, *p>0.05) compared to the control Fmr1 KO (n=4;93.07 % ± 8.4
of the wild type ) (Figure 4.7 B and C). These data demonstrate that the Ube3a was
successfully delivered and expressed in the hippocampus of Fmr1 KO mice suggesting
that the observed change in the behavior was specific of the AAV-mediated Ube3a
upregulation.

4.5 Discussion
Evidence connects FMRP to various forms of synaptic plasticity such as mGluRLTD, LTP priming and synaptic scaling that fully or partially relies on protein translation
(Sidorov et al. 2013). The identification and analysis of FMRP targets became a
necessary step in understanding the role and function of FMRP in the neuronal network.
To date, over 800 RNAs that interact with FMRP have been isolated from the brain of 2
week old animals. Interestingly, 23% of these RNA are located postsynaptically where
they code for a variety of proteins especially the elements of NMDAR or mGluR
intercoms (Darnell et al. 2011). An additional study that utilized high-throughput
screening of distinct RNA-recognition elements that bind FMRP revealed that
approximately 100 ASD-related genes that are also involved in Rett, Prader-Wili and
Angelman syndromes (Ascano et al. 2012). This discovery emphasizes the possibility
that molecules involved in these neurodevelopmental disorders ultimately belong to the
same cellular pathways that are responsible for normal learning and memory.
In the present study we determined if any connections exist between AS and
FXS through the interaction of Ube3a and FMRP, respectively. We examined Ube3a in
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synaptoneurosomes of Fmr1 KO mice and discovered a significant reduction in Ube3a
expression. Moreover, we studied the DHPG-induced alteration of Ube3a in crude
synaptoneurosomes isolated from the cortex of 3-4 month old wild type and transgenic
littermates. Similarly to other FMRP targets such as Arc (Niere et al. 2012), PSD 95
(Todd et al. 2003) and STEP (Zhang et al. 2008), we observed the mGluR1/5 specific
Ube3a up-regulation in wild type samples at 30 minutes post DHPG application. On the
contrary, DHPG failed to induce comparable changes in Ube3a in Fmr1 KO preparation
suggesting that FMRP is required for mGluR1/5-dependent protein translation of
synaptic Ube3a. However, the qRT-PCR analysis did not uncover a direct interaction
between Ube3a mRNA and FMRP suggesting that Ube3a levels may not be directly
mediated
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FMRP.
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immunoprecipitation has been a laborious task, the outcome of which greatly depends
on the IP conditions. For example, a high concentration of monovalent cations can
interfere with the RNA-protein interaction and/or produce non-specific results (Zalfa et al.
2003; Iacoangeli et al. 2008). Nonetheless, this suggests a possibility that further
optimization of IP conditions or utilization of younger animals could yield more positive
results. Meanwhile, the decrease in Ube3a expression could be potentially explained by
the impaired Ube3a trafficking to the dendrites or an abnormal Ube3a transcription
caused by the alterations in one of the FMRP-dependent proteins. Future work that
clarifies how FMRP regulates the levels of Ube3a, may prove critical to our
understanding of both AS and FXS.
The majority of research directed towards elucidating FMRP function has been
conducted in the young (2 week old or 2 month old) FMRP deficient animals (Darnell
and Klann 2013). Multiple studies suggest that the alteration in FMRP-bound RNA and
protein expression depends on the brain region, age, and sometimes an animal‘s
genetic background. For instance, PSD 95 and GluR1 protein expression show no
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difference in the neocortex of 2 week old and 2 month old C57 Fmr1 KO (Schütt et al.
2009), while PSD 95 was found to be significantly downregulated in the prefrontal cortex
of 2-4 month old C57 FMRP deficient animals. The developmental examination of Ube3a
mRNA and Ube3a protein in different cellular compartments in various brain regions
could provide more insight into the specific dysregulation of this protein in Fmr1 KO
animals and aid in understanding its involvement in the FXS pathology.
Our results show that the reduction in Ube3a protein in adult Fmr1 KO mice
could be a compounding factor that underlies FXS symptoms. Our laboratory previously
demonstrated that the delivery of wild type Ube3a via AAV9 viral vector appeared to be
beneficial as it rescued some of the synaptic plasticity and cognitive defects in Ube3a
deficient mice (Daily et al. 2011). Utilizing a similar strategy, we sought to investigate if
the increase in Ube3a could also normalize some of the cognitive deficits seen in FXS
mouse model. We delivered the wild type Ube3a-AAV to the hippocampus of adult Fmr1
KOs and assessed its effect through the behavioral output. The increase in wild type
Ube3a did not result in any changes in overall locomotor behavior, anxiety or social
interaction in Fmr1 KO injected with either Ube3-AAV or GFP control as they performed
comparable to wild type on the tasks. However, we observed a significant decrease in
freezing rates in the Fmr1 KO + Ube3a-AAV group when compared to Fmr1 KO + GFPAAV controls suggesting that elevated Ube3a levels could be detrimental to cognition.
Interestingly, no change in water maze performance was detected between experimental
groups implying that an increase in Ube3a exacerbated already present deficits but did
not affect normal hippocampal-dependent behavior.
Paternal Ube3a undergoes an energy-expensive complex epigenetic silencing in
order to maintain an optimal dosage of Ube3a that is required for normal brain function.
Any alteration in maternal Ube3a expression leads to abnormal changes in cellular
biochemistry resulting in either AS or ASD. Ube3a deficient animals exhibit motor and
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learning and memory impairments while a duplication Ube3a mouse model is
characterized by an increase in

repetitive behavior and impaired social interaction.

(Nakatani et al. 2009; Smith et al. 2011). The increase in Ube3a expression in the
hippocampus of Fmr1 KOs via viral injection resembles the latter condition. Interestingly,
we did not observe any changes in social behavior or marble burying tests. This could
be explained by a targeted to hippocampus protein delivery. It is likely that more wide
spread viral distribution is necessary to affect more complex behaviors. Nevertheless,
the decrease in fear conditioning performance in Fmr1 KO + Ube3a-AAV group provides
an additional support to the idea that optimal Ube3a expression is crucial for learning
and memory processes.
In summary, Ube3a has already been implicated in development and aging;
however, the study of Ube3a function in CNS has been limited to the AS mouse model.
As we propose a more general role of Ube3a in the overall mechanisms for modulating
synaptic efficacy and strength, we could only speculate if Ube3a could contribute to a
variety of diseased states including but not limited to FXS.
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Table 4.1 Summary of physiopathology in the AS and FXS mouse models.
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Figure 4.1. Synaptic Ube3a is decreased in the hippocampus of Fmr1 KO mice. A
and B. Immunohistological analysis revealed no change in total Ube3a expression in the
hippocampus of 3-4 month old Fmr1 KO (n=8) and wild type littermates (n=8). C and D.
Ube3a was significantly reduced in synaptoneurosomes isolated from hippocampus of
adult Fmr1 KO (n=4) and wild type controls (n=5). PSD 95 and GluR1 expression was
also decreased in the same sample. No change in tubulin (loading control) was
detected. Anti-FMRP antibody was used to determine the correct genotype. (Student ttest, *p>0.05, ** p>0.01)
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Figure 4.2. Synaptic Ube3a expression is upregulated in response to mGluR1/5
stimulation in wild type but not in Fmr1 KO animals. A. The filtration methods used
for synaptoneurosome preparation yielded fairly pure fractions as enrichment of PSD 95
and Synaptophysin (SNF) was observed in crude synaptoneurosomal fraction (SNS) but
not in the total homogenates (HOM). B. 30 μM DHPG was used to induce mGluR1/5
activation in synaptoneurosomes isolated form cortex of adult wild type (n= 2 animals). A
significant increase in Ube3a and PSD 95 was found in DHGP treated samples 30
minutes post application (n=8) compared to the NT group (n=6). mGluR1/5 specificity
was determined by blocking mGluR1/5 with 1 mM of MGPG. No differences were
detected in Ube3a and PSD 95 in MCPG pre-treated samples (n=3). C. A similar
experiment was conducted with Fmr1 KO (n=2 animals). DHPG failed to induce any
changes in Ube3 expression (n=6). (One way ANOVA, *p>0.05, ** p>0.01).
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Figure 4.3. The increase in Ube3a expression in Fmr1 KO mice didn’t affect the
anxiety behavior. Anxiety related behaviors were assessed by 5 minute elevated arm
maze test. A. No difference in time spent in open arm (OA) between WT type (n=7) and
Fmr1 KO injected with either Ube3a-AAV (n=8) or GFP-AAV (m=8) was detected. B.
Fmr1 KO + GFP-AAV mice showed a significant decrease in time spent immobile. C.
Occupancy plots represent the combined movement of all the animals in a group (One
way ANOVA, *p>0.05).
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Figure 4.4. The delivery of exogenous Ube3a to the hippocampus of Fmr1 KO mice
didn’t influence the locomotor behavior. A 15 minute open field test was conducted to
evaluate overall animal activity. A. Fmr1 KO injected with either Ube3a-AAV (n=8) or
GFP-AAV (n=8) exhibit hyperactivity and showed significant increases in distance
traveled compared to wild type control group (n=7). B. No statistically significant
differences were observed between any of the groups in the time spent in the center.
However, a trend was identified in Fmr1 KO + Ube3a-AAV mice (One way ANOVA,
**p>0.01). C. Representative occupancy plots.
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Figure 4.5. The associative but not spatial memory is affected by the increased
Ube3a expression in Fmr1 KO mice. A. Contextual fear conditioning was used to test
associative memory the 24 hour context test revealed a genotypic difference between
wild type (n=7) and Fmr1 KO mice. Additionally, a statistical decrease in freezing rates
was observed in Fmr1 KO animals injected with the Ube3a-AAV (n=8) compared to the
GFP injected controls (n=8). B. All the groups perform equally well on the 24 hour
probe trial in the hidden platform water maze test. C. Representative occupancy plots
of the 60 second 24 hour probe trail in the water maze test.
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Figure 4.6. No genotypic or treatment differences were detected in social
interaction or marble burying tests. A. Marble burying test was conducted to assess
anxiety, neophobia or compulsive behaviors. All the treatment groups performed
ccomparable to the wild type. B. Social interaction evaluated by the Crowley social
interaction test was normal among the animals (WT type (n=7); Fmr1 KO + Ube3a-AAV
(n=8); Fmr1 KO + GFP-AAV (n=8).
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Figure 4.7. Ube3a-AAV expression in Ube3a m-/p+ and Fmr1 KO mice. Ube3a m/p+ animals were used to evaluate Ube3a-AAV expression. A. Ube3a-AAV (n=4) or
GFP-AAV (n=3) control vector was injected into the hippocampus of Ube3a m-/p+
animals. The protein expression and distribution was determined 5 weeks post injection.
B–C. Western blotting revealed an increase in AAV-mediated Ube3a expression in the
hippocampus of Fmr1 KO mice (n=4) compared to GFP controls (n=4)(One way
ANOVA, *p>0.05).
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CHAPTER 5: DISSCUSSION

“If our brains were simple enough for us to understand them, we’d be so
simple that we couldn’t.”
-

Ian Stewart, The collapse of Chaos: Discovering Simplicity in a Complex
World

“The more I learn, the more I learn how little I know.”
-

Socrates

For many years the molecular mechanisms underlying protein degradation
remained a mystery until lysosomes and later the ubiquitin-proteasomal system (UPS)
were discovered (De Duve et al. 1953; Ciehanover et al. 1978). Modern neuroscience
now takes for granted an astonishing high rate of continuous protein synthesis and
degradation that is required for adequate neuronal existence. The UPS is involved in a
growing list of essential biological processes including, but not limited to, cell cycle,
transcription and overall quality control of proteins in somatic cells as well as in neurons
(Ciechanover 2005; Weissman et al. 2011). The mammalian brain is unique and
complicated piece of machinery that constantly undergoes structural and compositional
modifications in response to the sensory and emotional experiences. The neuronal
activity drives synaptic remodeling to accommodate and support molecular changes
required for long-lasting synaptic plasticity. The reorganization of synapses is
accomplished by protein translation, transcription and degradation. It is not surprising
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that a malfunction of one of the UPS components can disrupt normal neuronal
functioning leading to a variety of overt symptoms. Thus, many neurodegenerative
diseases such as Alzheimer‘s (Keller et al. 2000; Keck et al. 2003), Parkinson‘s (Kitada
et al. 1998; Vila and Przedborski 2004) and Amyotrophic lateral sclerosis (Kabashi et al.
2008) are linked to a dysfunctional protein clearance. Moreover, some autistic behavioral
phenotypes are thought to originate from defective ASD-related genes that are involved
in protein turnover (Baron et al. 2006; Lehman 2009). However, no other single protein
demonstrates the importance of UPS proteins in cognition than Ube3a. A point mutation
in a catalytic domain of Ube3a, an E3 substrate specific ligase, results in one of the most
severe forms of mental retardation (Matsuura et al. 1997; Yamamoto et al. 1997).
However, it is important to note that it remains unsubstantiated whether Ube3adependent alterations in the UPS are ultimately responsible for the AS phenotype.
Out present work was design to broaden the knowledge of Ube3a and its
contribution to learning and memory. It has been well established that neuronal activity
modulates protein composition. The increase in neuronal activity leads to the increase in
the ubiquitin-conjugated proteins and subsequent activation of proteasome-regulated
proteolysis as a mechanism for maintaining optimal protein levels and a compliment of
functioning proteins (Ehlers 2003; Yi and Ehlers 2005; Bingol and Sheng 2011). Nearly
all research of Ube3a in the mouse model established learning and memory defects, as
well as synaptic dysfunction, but molecular pathways and protein alterations following
neuronal activity or depolarization has not been well explored. Taking this into
consideration, we sought to examine if Ube3a is subjected to similar regulation following
synaptic activation via KCl depolarization and fear conditioning training. Our results
demonstrated that like many other molecules, Ube3a is sensitive to change in neuronal
activity. Recent publication already described an increase in total Ube3a protein
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following the exposure to a novel environment (Greer et al. 2010); however, our study
took one step further and examined the response of the paternal and maternal Ube3a to
the fear conditioning training. We detected both elevated expression in maternal and
paternal Ube3a starting 1 hour after the fear conditioning training. This data raises some
of the important questions i) what modulates activity-dependent Ube3a increase and ii)
what role the paternal Ube3a plays in the synaptic plasticity?
The alterations of Ube3a could originate from a translation of pre-existing mRNA
or from a newly transcribed gene. The 1-3 hour temporal increase suggests the latter
situation. The analysis of DNA promoter region of Ube3a identified the presence of
myocyte enhancer factor 2 (MEF2) binding site (Greer et al. 2010). The chromatin
precipitation showed a direct interaction between MEF2 and isoform 1 and 3 of Ube3a.
Moreover, the lentiviral injection with siRNA directed against MEF2A and MEF2D
resulted in significant reduction of Ube3a protein, suggesting that Ube3a might be
controlled by the MEF2-dependent gene regulation. Another protein MeCP2 could also
be considered a potential candidate for Ube3a transcriptional regulation. Mutations in
MeCP2 produce similar to AS symptoms implying a possible molecular association
between these two proteins (Watson et al. 2001; Hitchins et al. 2004). To date, the
connection between Ube3a and MeCP2 is controversial. Several publications reported
either increase or decrease in Ube3a in MeCP2 KO animals (Makedonski et al. 2005;
Samaco et al. 2005; Jordan and Francke 2006; Lawson-Yuen et al. 2007). The
discrepancies could be attributed to the animal age and an experimental procedure;
therefore, more data is needed to come to a more supported and solid conclusion.
Despite the possibility that MEF2 or MeCP2 controls activity-dependent Ube3a
transcription in wild type animals, it will be important to better understand if this is the
same process that governs paternal Ube3a expression. This becomes a particularly
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sensitive issue in light of the effort and progress to reactivate, or ―unsilence‖ the paternal
allele as a therapeutic strategy in the treatment of human AS.
Our observations of the increased paternal Ube3a in the hippocampus of Ube3aYFP mice following fear conditioning raises some critical issues about the paternal
Ube3a. First, it was unclear if the slight protein seen in Ube3a m-/p+ mice or in the post
mortem brains of AS patients was due to neuronal sources. In situ hybridization was
inconclusive as to the source of paternal expression. Here we find that paternal Ube3a
protein increases following fear conditioning; thus, at least some, if not all, of the
detectable Ube3a from the paternal allele is neuronal if not synaptic. Second, the
regulation of paternal expression following fear conditioning suggests a possible role for
paternal Ube3a in normal neuronal function. Is this slight increase possible to have a
role in learning and memory? This is a valid question since slight changes in Ube3a
protein at the synapse may have a quite significant effect. This may already be
supported by the evaluation of the severity of symptoms in AS patients. A small
percentage of AS individuals who have two times normal paternal expression through
uniparental paternal disomy (inheritance of two paternal alleles) or a methylation defect
show a milder phenotype then deletion patients.
One critical caveat to these studies exists in utilization of an Ube3a-YFP reporter
animal. Specifically, the addition of the YPF tag to the C-terminus of Ube3a caused a
significant reduction of the paternal Ube3a-YFP protein when compared to the paternal
wild type Ube3a obtained from the maternal Ube3a-YFP crosses. The reasons for this
reduction are not clear. The change in Ube3a protein conformation produced by the
addition of YFP may lead to higher than normal protein degradation. Additionally, the
alteration to Ube3a gene may interfere with the Ube3a transcription resulting in lower
RNA production and protein translation. Nevertheless, the fact that the stringent
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epigenetic control of paternal Ube3a protein can be overcome by neuronal activation is
an exciting discovery. The biological mechanisms responsible for the activity-dependent
increase in the paternal Ube3a are widely unknown. It is a possibility that alterations in
transcription rates between pUbe3a and Ube3a-ATS are altered in a way allowing a
small fraction of pUbe3a to undergo transcription. Alternatively, neuronal activity may
lead to chromatin modification through a wide variety biochemical cascades; this,
subsequently, could promote overall protein transcription including pUbe3a allele. In
recent years a paternal Ube3a became a desired pharmacological target in AS research
(Huang et al. 2011); however, many questions concerning a silent paternal allele, its
distribution, isoform production and function should be addressed before considering it
as a potential therapeutic. This pilot study nicely lays a foundation for additional
investigation that would aim to expand our understanding of the paternal Ube3a in
complex behaviors.
Whole cell homogenates used in our experiments offered only a general idea of
Ube3a expression in an activity-dependent context. In future, immunostaining of various
brain regions would provide details as the precise location of Ube3a activation and
paternal Ube3a expression origin (glial vs neuronal). Additionally, the degree of paternal
Ube3a activation is important, considering that fear conditioning activates only a small
number of neurons in the hippocampus (Strekalova et al. 2003; Huff et al. 2006). A
transgenic mouse fos-GFP crossed with a Ube3a-YFP mutant could be utilized to
investigate localization and expression of paternal or maternal Ube3a in active neurons
during specific behavioral task (Barth et al. 2004). The study of the paternal Ube3a
activated by neuronal activity might be instrumental in elucidating complex mechanisms
underlying the imprinting.
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In Chapter 2 we determined that activity-dependent ERK 2 phosphorylation is
affected by the Ube3a disruption. Several kinases implicated in learning and memory
has been previously examined in Ube3a deficient mouse model. Only alterations in
CaMKII such as decreased activity and abnormal phosphorylation were found in the AS
hippocampus at basal state (Weeber et al. 2003). Interestingly, the study failed to
identify deficits in other kinases including ERK 1/2 providing an additional value to the
activity-dependent approach. However, our initial ERK study needs further elaboration to
determine specific molecular pathways that are responsible for the decreased ERK
function. Chapter 3 shows normal ERK response to mGluR1/5 stimulation, suggesting
that the alternation in ERK phosphorylation is signal transduction specific. It has been
established that MEK 1/2 directly phosphorylates ERK1/2. Interestingly, our study didn‘t
identify any changes in activity-dependent alterations in MEK phosphorylation. Abnormal
ERK dephosphorylation or altered cellular ERK 1/2 distribution may partially explain this
phenomenon. First, several phosphatases such as PP1 and PP2A has already been
implicated in the pathology of AS. Taking this into consideration, it is a possibility that the
activity-induced phosphorylation / dephosphorylation equilibrium has been compromised
leading to the reduced ERK phosphorylation. Second, Ube3a loss could also result in
the abnormal cellular ERK 1/2 distribution that could prevent or impede direct interaction
between these two kinases. However, at the present time, more experimentation is
needed to clarify these hypotheses.
A variety of block and rescue experiments could be designed to dissect out a
source of ERK pathology and analyze its effect on the downstream of ERK cellular
cascades. This information may be critical and could provide some alternative
explanation to the abnormal cognition seen in Ube3a m-/p+ mice. For example,
ERK/MAPK pathway has been implicated in the regulation of gene induction through the
histone modification in CA1 area of the hippocampus after fear conditioning (Chwang et
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al. 2006). The abnormal activity-dependent gene transcription caused by a disrupted
ERK activation may explain why AS mice have deficit in long term but not short-term
memory. However, more investigation is needed to test this hypothesis.
In Chapter 3 we establish that the Ube3a m-/p+ mice exhibit reduced NMDAdependent and NMDA-independent LTD suggesting that Ube3a plays broader role in
overall synaptic function and is required for both synaptic potentiation and depression.
We hypothesized that the increase in immediate early gene Arc is likely a cause of the
reduced mGluR-LTD. The relationship between Ube3a and Arc remains elusive. It has
been shown that Ube3a does not directly ubiquitinate Arc but rather acts as its
transcriptional activator (Greer et al. 2010; Kühnle et al. 2013). The lack of solid
evidence about Ube3a and Arc interaction makes it more difficult to determine if
abnormal Arc expression is exclusively responsible for the mGluR-LTD deficits observed
in Ube3a m-/p+ mice. One way to clarify this is to create a Ube3a m-/p+ /Arc -/+ double
knockout mouse. The rescue of the synaptic depression in the double mutants would
indicate the Arc-dependent mGluR-LTD deficit. Alternately, no change in LTD
expression would suggest that loss of Ube3a perturbs different molecular mechanisms
controlling synaptic depression. The thorough examination of LTD signal transduction
pathways will provide a more complete picture of Ube3a actions in the regulation the
synaptic plasticity.
Based on our results, we posit that increased Arc leads to an occlusion of LTD.
In other words, the synapses of the Ube3a m-/p+ hippocampus are already in a
depressed state. Thus, the amount of induced LTD is reduced compared to that in wild
type mice and presents as an LTD deficit. This is supported by previous research
showing that saturating HFS results in LTP equivalent to that in litter mate controls. This
raises the interesting question of the importance of the LTD defect in the overall AS
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mouse phenotype. There are now four instances in the literature where the LTP and
learning and memory deficits have been rescued.
1)

Protein replacement with a AAV-Ube3a construct ( Daily et al. 2011);

2) Alterations in alpha CamKII at threonine 305/306 (van Woerden et al. 2007);
3) Application of ErbB inhibitors (Kaphzan et al. 2012);
4) Genetic decreas of α1 subunit of Na/K ATPase (a1-NaKA) (Kaphzan et al.
2013).
The rescue with the alpha CamKII TT305/306V a point mutation double mutant animal
was the original report. In hindsight, and keeping in mind the LTD defect we observed,
the rescue may be due to the presence of more active CaMKII. This would result in
overcoming the occluded LTD and perhaps counteracting the increase in Arc. Thus, the
CaMKII molecule is not the site of action, but rather what activated CaMKII does. In this
case, increase AMPA insertion and make the synapse more reactive to stimulation and
potentiation. A recent report shows that the genetic reduction of α1 NaKA through a
double cross (Ube3a m-/p+ / α1-NaKA -/+) reversed LTP and cognitive deficits in AS
mouse models. The mechanism of this rescue is still unknown; however, it has been
hypothesis that the decrease in α1-NaKA expression leads to normalization of
decreased excitability caused by excessive hyperpolarization. The alterations in intrinsic
neuronal membrane properties (increased hyperpolarization) may result in abnormal
threshold not only for induction of LTP but for LTD as well. These studies support the
idea that occlusion of LTD may underlie many of phenotypes of the AS mouse model
and may play a role in the cognitive disruption in human AS.
Recent research has linked mGluR-LTD to a variety of disorders including
Parkinson‘s, Alzheimer‘s, Fragile X Mental Retardation (FXS), and drug addiction
(reviewed in Lüscher and Huber 2010). Interestingly, AS and FXS show overlapping
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symptoms in humans and mice. Additionally, analogous disregulation of cellular
pathways such as increase in Arc and abnormal AMPAR distribution provide additional
evidence of molecular convergence in these diseased conditions (Niere et al. 2012). In
Chapter 4 we attempted to elucidate the role of Ube3a in FXS pathology. We found the
decrease in synaptic Ube3a level in the hippocampus of adult Fmr1 KO suggesting that
some of the biochemical and behavioral phenotypes described in this mouse model
could originate from the Ube3a deficiency. Moreover, synaptoneurosomes stimulation
with DHPG induced Ube3a translation in wild type animals but not in Fmr1 KO samples
support the possibility of a Ube3a mRNA and FMRP connection. However, FMRP coimmunoprecipitation failed to detect such an interaction.
The analysis of Ube3a mRNA in dendrites or in the actively translated
polyribosomes could shed more light on the FMRP and Ube3a link. While we observed a
reduction in Ube3a, we sought to determine if the Fmr1 KO cognitive defects could be
rescued by the addition of exogenous Ube3a via AAV9 viral vector. The behavioral
testing revealed that increase in Ube3a negatively affected contextual fear conditioning.
This experiment, however, harbors a few caveats. One of them is the difficulty to
determine how much of the exogenous Ube3a is expressed from the virus in the Fmr1
KO mice. We can easily differentiate Ube3a-AAV expression in the brain of AS mice;
however, amount or location of Ube3a-AAV expression could not be resolved from the
endogenous Ube3a product due to the absence of any molecular tag on Ube3a-AAV
construct. Lastly, the detected decrease in Ube3a was synapse-specific. It is feasible to
hypothesize that the supplementation with Ube3a could alleviate some of the symptoms
when it is delivered specifically to the synapses and does not increase the total Ube3a
protein through the cell mimicking ASD conditions (Nakatani et al. 2009; Smith et al.
2011).
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In summary, what lessons have we learned about Angelman Syndrome using
these novel approaches? First, the contribution of Ube3a to basal and activity induced
synaptic strength is much greater than was previously thought as it presents as a deficit
for both LTP and LTD. Second, Ube3a likely plays roles beyond the constitutively
expressed housekeeping protein in light of its activity-dependent alteration in response
to neuronal activity. Third, Ube3a doesn‘t necessarily need to target a specific protein to
be involved in altering its activity as seen in ERK phosphorylation, a kinase central to
mechanisms involved in learning and memory. Forth, Ube3a may potentially contribute
to different childhood neurodevelopmental disorder such as FXS emphasizing the
significance of studying Ube3a outside the context of AS. Finally, the identification of
major convergent pathways that underlie AS and other neurodegenerative or
neurodevelopmental disorders may prove to be an alternative strategy for the future drug
discoveries as it would simultaneously provide pharmacological targets for multiple
conditions.
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